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ABSTRACT
DEVELOPMENT OF BAR-PEPTIDE NANOPARTICLES AND ELECTROSPUN
FIBERS FOR THE PREVENTION AND TREATMENT OF ORAL BIOFILMS
Mohamed Yehia Mahmoud
April 18, 2019
Background: Periodontal diseases are globally prevalent inflammatory disorders
that affect ~47% of U.S adults. Porphyromonas gingivalis (Pg) has been identified
as a “keystone” pathogen that disrupts host-microbe homeostasis and contributes
to the initiation and progression of periodontitis. Pg associates with oral
streptococci in supragingival plaque and this interaction represents a potential
target for therapeutic intervention. Previously our group developed a peptide
(designated BAR), that potently inhibits Pg/Streptococcus gordonii (Sg) adherence
in vitro and Pg virulence in a murine model of periodontitis. While efficacious, BAR
(SspB Adherence Region) provided transient inhibition and required higher
concentrations of BAR to disrupt established biofilms.
Hypothesis and Aims: To address these challenges, we hypothesized that BARsurface modified and BAR-encapsulated poly(lactic-co-glycolic acid) (PLGA)
nanoparticles (NPs) may more potently inhibit and disrupt biofilms in vitro and in
vivo, relative to free BAR.
vi

In addition, a new rapid-release platform, composed of polymeric electrospun
fibers (EFs) that encapsulate BAR peptide, was developed. Given this, our
objectives were to evaluate BAR-surface modified NPs in a murine model of
periodontitis; to fabricate and assess the ability of BAR-encapsulated NPs to inhibit
and disrupt in vitro oral biofilm formation, and to evaluate a new dosage form,
electrospun fibers, to inhibit andformation, and to evaluate a new dosage form,
electrospun fibers, to inhibit and disrupt in vitro oral biofilm formation. In addition,
the safety of all platforms was determined via viability, apoptosis, adenosine
triphosphate (ATP), lactate dehydrogenase (LDH) and oxidative DNA assays
using telomerase immortalized gingival keratinocytes (TIGKs).
Methods: BAR-encapsulated and BAR-surface modified PLGA NPs were
synthesized using adapted double- and single-emulsion techniques, respectively.
Electrospun fibers were formed using a uniaxial approach, with different
hydrophobic polymers (PLGA, polycaprolactone, poly(L-lactic acid)); each blended
with different polyethylene oxide ratios (PEO: 0, 10, 20, or 40% w/w) to achieve
maximal release of BAR. Both BAR-encapsulated NPs and EFs were assessed
for inhibition of two-species biofilm formation and for disruption of pre-existing
biofilms, against an equimolar free BAR concentration. In vivo efficacy of BARsurface modified NPs was assessed using a murine model of periodontitis by
measuring alveolar bone resorption and gingival IL-17 expression as outcomes of
Pg-induced inflammation.
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Results: BAR-encapsulated NPs and EFs inhibited biofilm formation (IC50s = 0.7
and 1.3 μM, respectively) in a dose-dependent manner, relative to free BAR (IC50
= 1.3 µM). In addition, BAR-encapsulated NPs and EFs efficiently disrupted
established dual-species biofilms (IC50s = 1.3 and 2 μM, respectively). Treatment
of Pg/Sg infected mice with BAR-surface modified NPs reduced alveolar bone loss
and IL-17 expression almost to the levels of sham-infected mice and to a greater
extent than treatment with an equimolar amount of free BAR. The in vitro
cytotoxicity studies, which utilized the maximum concentration of BARencapsulated NPs, BAR-surface modified NPs, BAR EFs, and free BAR (1.3 and
3.4 μM) demonstrated > 90% viability for all samples and showed no significant
lysis or apoptosis relative to untreated cells. In addition, all tested formulations
exhibited a lack of hemolytic activity.
Conclusion: These data suggested that BAR NPs and EFs provide novel and
potent platforms to inhibit and disrupt dual-species biofilms. All formulations
exhibited minimal cellular toxicity or hemolytic activity, highlighting the potential of
NPs and EFs as a biocompatible platform for translatable oral biofilm applications.
Chapters included in this dissertation represent papers that have been submitted,
which may result in duplicate descriptions across chapters; however, these have
been provided for the sake of completeness. Chapter 2 has been published in the
Journal of Nanobiotechnology and Chapter 3 has been published in the Journal of
Controlled Release. It is the intent to publish Chapters 4 and 5 in the near future.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
Periodontal diseases are multifactorial common chronic diseases that
destroy the tooth-supporting tissues and subsequently lead to alveolar bone loss
and finally tooth loss. Periodontal diseases are also associated with increased risk
for multiple systemic diseases including cardiovascular disease, diabetes,
rheumatoid arthritis, pulmonary disease, and obesity1,2. Periodontal diseases are
globally prevalent diseases with the worldwide economic impact of direct treatment
estimated at US $298 billion yearly, corresponding to an average of 4.6% of global
health expenditures3-6.
Gingivitis is a mild form of periodontal disease that is caused by bacterial
colonization in the subgingival pocket leading to the formation of a biofilm (dental
plaque). Gingivitis is usually diagnosed through the clinical signs of inflammation
(erythema, edema, pain), bleeding and discomfort on gentle probing, and halitosis.
Chronic gingivitis often results in mild bleeding from the gums during tooth
brushing, which is generally only a minor inconvenience unless underlying blood
dyscrasias or bleeding disorders exist7. Gingivitis is a reversible disease that can
be resolved following treatment of gingival inflammation by proper oral health care
to reduce gingival pocket depths to ≤ 3 mm.
1

An acute form of gingivitis (necrotizing ulcerative gingivitis) is characterized
by gingival necrosis, bleeding, ulcerated papillae, severe gingival swelling and
pain. Untreated ulcerative gingivitis may lead to rapid destruction of the
periodontium resulting in necrotizing ulcerative periodontitis and can even spread
as necrotizing stomatitis, into neighboring tissues in the cheeks, lips or the bones
of the jaw8. Untreated gingivitis and poor oral health care can progress to
periodontitis which exhibits a chronic inflammatory response that ultimately results
in the destruction of connective tissue, resorption of alveolar bone and tooth loss7.
Chronic periodontitis results in irreversible tissue damage that remains for life and
requires diligent protective care to prevent disease recurrence9. Individuals with
advanced periodontitis may also have recurrent periodontal abscesses and
halitosis. The clinical diagnosis of chronic periodontal disease depends on visual
and radiographic assessment of the periodontal tissues, and measurements of
subgingival pocket depths (≥ 5 mm)7.
Aggressive periodontitis results in more rapid attachment loss and bone
destruction and can occur earlier in life, often in children as young as 8 yr old.
Secondary characteristics of aggressive periodontitis are described by the
presence of relatively low levels of gingival bacteria although commonly,
Aggregatibacter actinomycetemcomitans and Pg are the most abundant
organisms associated with the disease10. In addition to rapid and severe
periodontal tissue destruction, aggressive periodontitis is characterized by a
hyper-responsive phenotype characterized by an increased inflammatory
response upon stimulation of innate immune cells11.
2

Periodontal diseases are also associated with a variety of systemic
conditions. For example, periodontal diseases are associated with preterm births,
which might be attributed to infection of decidual tissues by periodontal pathogens
through bacteraemia or to an inflammatory cascade that results from systemic
circulation of inflammatory mediators produced in the periodontal tissues 12.
Previous studies demonstrated that intravenous injection of pregnant mice with
periodontal bacteria leads to premature delivery and stillbirths13. However, it is
important to note that currently there is no direct causal evidence that periodontal
pathogens can cause preterm birth in humans and these organisms are not
associated with chorioamnionitis, positive placental cultures, or markers of upper
genital tract inflammation14.
Periodontal diseases may also have a potential role in the initiation or
progression of coronary artery disease and stroke15. These effects may be
attributed to increasing levels of C-reactive protein, fibrinogen, and cytokines,
which have been linked to atherosclerosis-induced disease. In addition, a previous
study showed that treatment of periodontal disease reduced serum inflammatory
markers and C-reactive protein16 and other studies demonstrated that periodontal
pathogens promote platelet aggregation and induce foam cell formation 17. Finally,
several additional studies suggested that a systemic antibody response to several
periodontal pathogens was associated with coronary heart disease, stroke, and
increased intima media thickening18-20.
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Periodontitis and rheumatoid arthritis are common chronic inflammatory
diseases with very high morbidity worldwide. Previous studies showed that
individuals with both periodontitis and rheumatoid arthritis may have more missing
teeth and greater inflammation relative to periodontitis patients without rheumatoid
arthritis21. Pg produces a proteolytic enzyme, Pg peptidyl-arginine deiminase
(PPAD), which has the ability to convert arginine residues in proteins to citrulline.
Citrullination of proteins can alter protein assembly and function and consequently
deregulate immune evasion. Moreover, chronic exposure to citrullinated proteins
that may exist in periodontitis patients may predispose susceptible individuals to
the development of autoantibodies and the initiation of rheumatoid arthritis22
Periodontal diseases are also a possible complication of diabetes.
Treatment of periodontal disease has been shown to enhance diabetic control23.
Periodontal disease might also be an important predictor of deaths from ischaemic
heart disease and diabetic nephropathy, but not from other causes24.
Finally, periodontal diseases may be associated with various pulmonary
infections25. Pathogens causing pneumonia have been shown to colonize the oral
cavity of high-risk individuals26, and initial studies indicate that proper oral hygiene
can reduce the rate of respiratory infections27.
The gold standard for treatment of periodontal disease is instrumental
debridement of dental plaque followed by antibiotic administration and surgery to
reduce subgingival pocket depth if necessary28,29. Although mechanical
debridement has proven effective for treating periodontal diseases 30, this approach
4

has several limitations, For example, individual patients may not respond uniformly
and favorably to treatment31, scaling instruments may be unable to fully penetrate
deep subgingival pockets, mechanical debridement may be ineffective against
certain pathogens, and the presence of other adverse conditions including tooth
loss, dentin hypersensitivity, and gingival collapse may decrease the effectiveness
of mechanical treatment strategies32,33. As a result, antibiotic administration, in
combination with mechanical debridement has been recommended to suppress
periodontal pathogenic bacterial colonization and improve clinical outcomes30,34.
Despite the advantages that adjunct localized or systemic antibiotics can
provide, these treatment strategies often exhibit non-specific activity and affect
beneficial organisms present in the oral cavity. Antibiotics may also fail to
effectively penetrate the oral biofilms. Additional potential risks include the
development of resistant species, emergence of fungal opportunistic infections,
and potential allergic reactions35-37.
Many factors can influence the initiation and progression of periodontal
disease including genetic predisposition, health status of the host, environmental
factors, and risk factors such as diet and stress. In addition, the subgingival
microbial community plays a vital role in periodontitis development. The role of
bacteria in periodontitis can be illustrated by two main hypotheses. The nonspecific plaque hypothesis suggests that no specific bacteria plays a role in
periodontitis development. This hypothesis postulates that the host innate immune
response keeps oral organisms and putative virulence factors under control and
5

disease only develops if the host immune response becomes compromised and
bacterial virulence factors can no longer be neutralized. Since plaque of any
composition can potentially cause disease, the best preventative approach would
be mechanical removal of plaque38.
In contrast, the specific plaque hypothesis purports that specific microbial
species are associated with periodontitis progression39. Early studies suggested
that many organisms might be associated with periodontitis, including protozoa,
spirochetes, streptococci; actinomyces, Gram-negative anaerobic organisms, and
facultative anaerobic Gram-negative organisms of the genera Capnocytophaga,
Eikenella and Actinobacillus40. More recently, Socransky et al. identified the ‘red
complex’ of organisms, composed of a group of three species including
Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia, and
showed that these organisms predominate

in the pathogenic dental plaque

isolated from symptomatic subgingival sites of periodontitis patients41. However, a
limitation of the specific plaque hypothesis is that it does not completely explain
the absence of putative periodontal pathogens in some diseased individuals or the
presence of these pathogenic organisms in healthy individuals 42. In addition, a
further limitation relates to the large number of uncultivable species43 in the oral
microbiome which creates bias toward easily cultivable species44. This hypothesis
proposed that the use of antibiotics against specific bacterial species could
potentially cure and prevent disease.
.
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More recently, a modified hypothesis has been proposed suggesting that
changes in environmental factors may lead to a shift in the resident microflora
resulting in microbial dysbiosis and that specific bacteria may contribute to the
disruption of normal host-microbe homeostasis. Indeed, Pg is a gram negative
anaerobic bacterium and has been found to be present in 88% of sub-gingival
plaque samples isolated from chronic periodontitis patients45. Pg has been
identified as a “keystone pathogen” due to its ability to disrupt the host complement
pathway, leading to a change in the microflora from a symbiotic microbiota to a
dysbiotic community even though Pg may be present in low abundance46,47. This
recent study demonstrated that Pg-infected mice showed reduced innate
immunity, increased oral microbial biomass, and significant changes in the
composition of the periodontal microbiota leading to the induction of inflammatory
bone loss. Consistent with the keystone pathogen hypothesis, Pg only induced
inflammatory bone loss in wild type mice and was avirulent in germ free animals
that lacked the indigenous oral microbiota48.
Although the keystone pathogen hypothesis was initially established from
studies conducted in a mouse model, it was consistent with observations in other
animal models and in humans42. For example, it was shown that infection by Pg
increased bacterial biomass of the dental biofilm in rabbit49 and the use of a
vaccine against Pg decreased total subgingival bacterial counts in non-human
primates (Macaca fascicularis)50. Pg has also been shown to alter the host immune
response in other ways as well. A previous in vitro study showed that Pg inhibits
the stimulation of gingival interleukin-8 like chemokines which may delay the
7

infiltration of neutrophils, consequently enabling its initial colonization and
enhancing the growth of other organisms51. This study also revealed that the
capability of Pg to persist in the periodontium relies on complement C5 convertase
activity of its proteolytic enzymes and destructive crosstalk between the C5a
receptor and toll-like receptor 248.
Pg initially adheres to primary colonizers of the oral cavity, i.e., commensal
streptococci (e.g., Streptococcus gordonii) before becoming established in its ideal
niche, the anaerobic environment of subgingival dental plaque 52. In efforts to
establish a more mechanistically-specific treatment or prophylactic modality, the
recent identification of pathogenic mechanisms in polymicrobial communities and
their relation to pathways of immune response have begun to elucidate targets
relevant to inflammatory and disease states. As stated above, biofilm formation
and bacterial colonization are initially prompted by association of Pg with oral
streptococci in the supragingival niche, and this represents an ideal target for
therapeutic intervention.
Previous studies suggested that Pg adherence to Sg is mediated by a
protein-protein interaction that occurs between the minor fimbrial antigen (Mfa) of
Pg and specific members of the antigen I/II family of proteins expressed by
commensal streptococci, e.g., the SspB protein of Sg (Figure 1.1)53. In addition,
the region comprising amino acid residues 1167 to 1250 of the SspB polypeptide
sequence was shown to be essential for adherence to Pg54 and additional studies
showed that within this region of SspB, amino acids 1167 to 1193 designated as
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BAR (SspB Adherence Region) were required for adherence of Pg53. These
studies also demonstrated that a synthetic peptide encompassing the BAR motif
potently inhibited biofilm formation by Pg and Sg in vitro and reduced virulence of
Pg in a murine model of infection [refs]. While efficacious, the effectiveness of BAR
as a potential therapeutic may be limited by the duration of exposure within the
oral cavity and the increased complexity of the oral microbiome in humans. Indeed,
higher concentrations of BAR were required to disrupt established in vitro
biofilms15,17. To address these delivery challenges, our goal was to develop a drug
delivery system for BAR peptide that specifically targets Pg while providing higher
localized concentrations, for longer duration in the oral cavity.

9

Figure 1.1 Mechanism of Pg–Sg co-aggregation. Adapted from Trends in
Molecular Medicine, 21(3), 172-183.
Despite the attributes that delivery vehicles offer to biologic and drug
delivery, there is currently a scarcity of drug delivery vehicles that enable specific
and prolonged delivery of active agents to the oral cavity. One option to provide
higher localized concentrations and prolonged delivery is to use polymeric
nanoparticles (NPs)55. The advantages of using NP delivery vehicles include the
ability to: 1) highly encapsulate and deliver one or multiple active agents
simultaneously; 2) protect the stability of active agents, especially molecules with
10

shorter half-lives (e.g. peptides); 3) provide tunable release and prolonged delivery
of active agent; 4) facilitate penetration to target specific niches in cells and tissue;
and 5) enable subsequent localization of active agent in target sites

56.

A variety of nanoparticle platforms exist, fabricated from metals 57,58,
semiconducting materials59, ceramics60-63, lipids64,65, and polymers66,67. For dental
applications specifically, metallic and metal oxide particles, made from silver 68-71,
gold72,73, copper74-76, zinc77,78 and titanium78 have demonstrated antimicrobial
properties in the oral microenvironment and have been utilized in the treatment of
periodontal diseases. However, this inhibition is non-specific in nature, resulting
from primarily electrostatic interactions with bacterial cells, subsequently
decreasing bacterial replication or reduction of ATP production79-81. Moreover,
there have been several concerns regarding the toxicity associated with metallic
NPs and their accumulation in various tissues and organs82-84.
Polymeric NPs have been widely utilized to deliver antibiotics to the oral
cavity85,86, and to avoid challenges of cytotoxicity and harmful accumulation of toxic
metabolites observed after administration of metallic NPs. Moreover, polymeric
NPs may offer biodegradability without toxic residues, and may be tailored to
control the rate and duration of drug delivery. These attributes may be helpful to
deliver high concentrations of active agents to target sites and to maintain
functional activity of these agents for prolonged durations. Last, polymer NPs may
be designed with mucoadhesive characteristics to adhere to oral tissue, thereby
increasing the local concentration of active agents55,56,61,66.
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PLGA NPs have been FDA-approved and widely studied for drugs, protein,
RNA and DNA delivery applications. PLGA NPs degrade into relatively inert
metabolic by-products, poly(lactic acid) (PLA) and poly(glycolic acid) (PGA),
enabling safe, biocompatible, and non-toxic delivery of associated cargo86-91. As
one example of antibiotic delivery, a previous study showed that minocyclineloaded PLGA NPs had potent antibacterial activity against Aggregatibacter
actinomycetemcomitans infection with a minimum inhibitory concentration two
times lower than free minocycline92.
Despite the utility of NPs to deliver antibiotics to treat periodontitis, high
doses of antibiotics are needed to establish inhibitory concentrations in the
subgingival pockets, which may result in antibiotic resistance and adverse side
effects37. Moreover, non-specific inhibition decreases the viability of commensal
flora in the oral cavity, potentially causing fungal, viral and other bacterial
infections. Due to these challenges, there is a need to develop targeted, sustainedrelease delivery vehicles that can specifically target Pg, a predominant pathogen
in severe periodontitis, and provide higher localized concentrations of active
agents for longer duration in the oral cavity93,94.
Our preliminary studies have suggested that PLGA NPs that are surfacemodified with BAR peptide increase the effectiveness of peptide-mediated
inhibition of Pg/Sg adherence. Recently we demonstrated that this increased
effectiveness is attributed to specific multivalent interactions between NPs and Pg.
BAR-modified PLGA NPs enhanced BAR potency by promoting a multivalent
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binding interface, thus increasing the avidity of BAR with Pg95,96. Building upon this
previous work, we next wanted to evaluate BAR-surface modified NPs in an in vivo
murine model of infection and to increase the duration of exposure by developing
sustained-release nanoparticles that control the release of BAR peptide to promote
longer exposure time (12-24 hr) in the oral cavity. Our premise was that the
incorporation of BAR peptide in PLGA NPs may provide sustained-release of BAR
peptide, while BAR-surface modification offered a platform that provides higher
localized concentration of BAR in the oral cavity.
Recently, polymeric electrospun fibers have been widely used in oral drug
delivery97,98. EFs may complement the delivery of, or offer advantages to NPs,
including higher drug loading; more tunable modulation of drug release, dependent
on the polymer properties; and less susceptibility to removal by salivary flow,
resulting in longer retention in the oral cavity99-101. A variety of natural, synthetic,
semi-synthetic and biological polymers are used to provide biocompatibility and
biodegradablility. FDA-approved polymers including PLGA102, poly(L-lactic acid)
(PLLA)103, polycaprolactone (PCL)97, and polyethylene oxide (PEO)104 have been
successfully used for drug delivery. In addition, fibers have the capacity to serve
as a more durable delivery vehicle, providing enhanced retention in the oral cavity
and ensuring active agent release within the oral cavity versus in the digestive
tract. This durability may also offer a more convenient administration method,
similar to films, but with the capability of providing prolonged release in desired
applications. Given these attributes, we envisioned that designing EFs targeted to
the oral cavity may provide a new dosage form in which to administer BAR, and
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may provide a mechanism to improve therapeutic outcomes by increasing the
localized concentration of BAR. We anticipated that completion of these aims
would increase BAR effectiveness and longevity of exposure without influencing
other commensal or beneficial bacteria that reside in the oral cavity. Moreover, the
successful achievement of these objectives will provide new platforms for the
delivery of BAR peptide in the oral cavity, with the potential to translate prevention
and treatment to clinical practice. We envision that these research outcomes will
have a significant impact on controlling a costly and widespread disease and may
more broadly impact the serious systemic conditions that are associated with Pg
infection.
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CHAPTER 2
BAR-ENCAPSULATED NANOPARTICLES FOR THE INHIBITION AND
DISRUPTION OF PORPHYROMONAS GINGIVALIS-STREPTOCOCCUS
GORDONII BIOFILMS
Introduction
Periodontal disease is a group of chronic inﬂammatory diseases commonly
caused by Porphyromonas gingivalis, Tannerella forsythia, and Treponema
denticola. Together these pathogens are known as the “red complex” 36. The
progression of periodontal disease can cause tissue destruction and tooth loss,
and if left untreated can contribute to systemic conditions of increased cancer risk,
cardiovascular disease, diabetes, rheumatoid arthritis, pulmonary disease, and
obesity1,2.
Current periodontal treatments aim to reduce bacterial plaque formation in
the oral cavity using primarily physical and chemical (antibiotic) methods 105,106.
However, current antibiotic treatment strategies exhibit non-specific activity,
affecting beneficial organisms also present in the oral microbiome. Additional
potential risks include the development of anti-bacterial resistant species,
emergence of fungal opportunistic infections or Pseudomonas infection, and
allergic reactions.
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Last, most current antibiotics have difﬁculty penetrating periodontal bioﬁlms,
and must be frequently administered, due to their transient activity in the oral
cavity35,37,107.
Pg has been found to be associated with chronic periodontitis in 88% of
sub-gingival plaque samples23. Moreover, Pg and Sg association enhances the
disruption of host–microbe homeostasis and induces population changes in the
subgingival biofilm, driving inflammatory periodontal diseases47,48,108. Previous
work in our group has shown that Pg adherence to streptococci is driven by the
interaction of the minor fimbrial antigen (Mfa) of Pg and the streptococcal antigen
I/II (AgI/II)109,110. From these studies, a peptide (designated BAR), was developed
that potently inhibits Pg/Sg adherence in vitro and reduces Pg virulence in a mouse
model of periodontitis111-113. While efficacious, one of the challenges to free BAR
administration is that it provides relatively transient inhibition of Pg in the oral
cavity. Moreover, to treat established biofilms, relative to initial biofilm formation,
higher concentrations of BAR are required.
Polymeric delivery vehicles provide one option to address these challenges,
by offering prolonged and targeted delivery of active agents. In particular, for
application to the oral cavity, polymeric nanoparticles are easy to fabricate and
produce stable formulations. From a delivery perspective, polymeric NPs may offer
rapid degradation in the acidic environment of the oral cavity, while providing
mucoadhesive properties due to the electrostatic interactions between NPs and
gingival epithelium114-116. Furthermore, for more labile molecules like biologics,
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polymers have the potential to protect the functionality of the active agent and
provide tunable release and prolonged delivery, while enabling localization of the
active agent to target sites115,117. In addition polymeric NPs may offer a safer and
more biocompatible delivery method, relative to currently applied metallic NPs that
exhibit broad antimicrobial effect118,119.
Previous work in our groups has demonstrated that NPs surface-modified
with BAR peptide more potently inhibit Pg adherence to Sg, relative to an
equimolar administration of free BAR peptide in vitro95. This increased potency
was attributed to a higher localized dose of BAR, facilitating multivalent interactions
with Pg. While surface-modified NPs provide targeting efficacy, a method of
delivering high concentrations of BAR for prolonged duration has not been
investigated. In this study, we sought to develop a formulation that encapsulates
and prolongs the delivery of BAR, for durations relevant to oral delivery. BARencapsulated PLGA NPs were characterized and evaluated in two-species biofilm
inhibition and disruption models. In addition, the kinetics of BAR-encapsulated,
relative to BAR surface-modified NPs were assessed in a two-species model.
Materials and Methods
Peptide Synthesis
BAR peptide is comprised of residues 1167 to 1193 of the SspB (Antigen
I/II) protein sequence of Sg (NH2-LEAAPKKVQDLLKKANITVKGAFQLFSCOOH)112. To enable peptide quantification and detection, the epsilon amine of
the underlined lysine residue of BAR was covalently reacted with 617

carboxyfluorescein to produce fluorescent BAR (F-BAR). Both unlabeled and
labeled peptides were synthesized by BioSynthesis, Inc. (Lewisville, TX) and
obtained with greater than 90% purity.
BAR-Encapsulated and BAR Surface-Modified Nanoparticle Synthesis
BAR and F-BAR encapsulated poly(lactic-co-glycolic acid) PLGA and
methoxy-polyethylene glycol (mPEG-PLGA) NPs were synthesized using a
double-emulsion technique89,120. Briefly, BAR was encapsulated in PLGA
carboxyl-terminated polymer (0.55–0.75 dL/g; LACTEL®; DURECT Corporation,
Cupertino, CA, USA) or mPEG-PLGA (Mw ~5,000:55,000 Da; PolySciTech®;
Akina, Inc., IN, USA) using laboratory facilities (Figure 2.1). One hundred
milligrams of PLGA or mPEG-PLGA was dissolved in 2 mL methylene chloride
(DCM) overnight. The next day, BAR was dissolved in 200 μL Tris EDTA (TE)
buffer at a concentration of 43 µg BAR/mg PLGA. The resulting PLGA/DCM
solution was vortexed while adding 200 μL of BAR peptide solution dropwise, and
the mixture was ultrasonicated. Next, 2 mL of the PLGA/DCM/BAR solution was
added dropwise to 2 mL of 5% (w/v) polyvinyl alcohol (PVA) while vortexing and
was subsequently sonicated. The NP solution was added to 50 mL of 0.3% PVA
for 3 hr to evaporate residual DCM. After evaporation, the NP solution was
centrifuged at 13,000 rpm at 4°C and washed with distilled water twice. F-BAR
encapsulated NPs were synthesized similarly, but were protected from light to
avoid photo bleaching.
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BAR surface-modified NPs were synthesized similarly as above using a
previously described double-emulsion technique (Figure 2.2)88,121,122. Briefly, the
5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 mL of 5 mg/mL avidinpalmitate and the 2 mL PLGA/DCM solution was added dropwise to 4 mL
PVA/avidin-palmitate while vortexing. After the first wash, the supernatant was
discarded and the pelleted NPs were resuspended in 10 mL PBS for 30 min on a
benchtop rotator, with biotinylated BAR peptide at a molar ratio of 3:1 BAR:avidin
(18.5 nmol/mg) in PBS. After conjugation, the NPs were washed two times with
distilled water by centrifugation at 13,000 rpm at 4°C. After washing, both BARencapsulated and BAR surface-modified NPs, were suspended in 5 mL of distilled
water, frozen at -80°C, and lyophilized.

Figure 2.1 Schematic representation of BAR-encapsulated NP synthesis.
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Figure 2.2 Schematic representation of BAR surface-modified NP synthesis.

NP Characterization: NP Morphology, Size, BAR Loading, Controlled
Release
Unhydrated NP morphology, diameter, and size distribution were
determined by analyzing scanning electron microscopy (SEM) images with NIH
ImageJ software (version 1.5a, imageJ.nih.gov). Dynamic light scattering and zeta
potential analyses were performed on hydrated NPs to determine the
hydrodynamic diameter and surface charge (Malvern, Malvern, UK). To determine
BAR loading and encapsulation efficiency (EE), NPs were dissolved in dimethyl
sulfoxide (DMSO). The quantity of extracted F-BAR was determined by measuring
fluorescence (488/518 nm excitation/emission). For BAR-encapsulated NPs, in
vitro release was measured by gentle agitation of NPs in phosphate buffered saline
(PBS, pH 7.4) at 37°C. At fixed time points (1, 2, 4, 8, 24, 48 hr), samples were
collected and the amount of BAR released from the NPs was quantified as
described above.
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Growth of Bacterial Strains
Pg ATCC33277 was grown in Trypticase soy broth (Difco Laboratories Inc.,
Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL
menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently
inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aerobically without shaking in brain-heart infusion broth (Difco Laboratories Inc.)
supplemented with 1% yeast extract for 16 hr at 37°C.
Biofilm Inhibition Assay
To assess the effectiveness of BAR-encapsulated NPs to prevent the
interaction of Pg with Sg, Sg was harvested from culture and labeled with 20 µL of
5 mg/mL hexidium iodide for 15 min at room temperature. Following incubation,
cells were centrifuged to remove unbound fluorescent dye. Subsequently, the
bacterial concentration was measured by the O.D. at 600 nm from twenty-fold
diluted cultures of Sg. The optical density of Sg cells was adjusted to 0.8 (1 x 109
CFU/mL) to obtain uniformity between cell counts in each well. After adjusting the
optical density, 1 mL of Sg cells was added to each well of 12-well culture plates
containing a sterilized micro-coverslip. The cell culture plates were wrapped in
aluminum foil to protect the labeled cells from light and placed on a rocker platform
in the anaerobic chamber for 24 hr.
Pg cultures were optimized using a similar approach, utilizing a different
fluorescent label (20 µL of 4 mg/mL carboxyfluorescein–succinylester). Pg was
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incubated with the fluorescent dye for 30 min on a rocker platform and protected
from light. The same procedures were followed as performed with Sg to determine
cell concentration, with slight adaptations. The optical density of Pg was adjusted
from 0.8 to 0.4 O.D. (5 x 107 CFU/mL) by diluting Pg cultures with an equal volume
of BAR NPs or free BAR. The final concentration of BAR NPs or free BAR ranged
from 0.3-3 µM based on the previously determined IC50 of free BAR (1.3 µM). Pg
was incubated with BAR NPs or free BAR at 25°C for 30 min before transferring to
wells containing Sg.
Plates containing Pg and Sg were subsequently incubated for 24 hr at 37°C
in anaerobic conditions95. The following day, the supernatant was removed and
cells were washed with PBS. Adherent cells were fixed with 4% (w/v)
paraformaldehyde and the cover glass was mounted on a glass slide. Biofilms
were visualized using a Leica SP8 confocal microscope (Leica Microsystems Inc.,
Buffalo Grove, IL) under 60x magnification. Background noise was minimized
using software provided with the Leica SP8 and three-dimensional z-stack biofilm
images were obtained from 30 randomly chosen frames using a z-step size of 0.7
μm. Images were analyzed with Volocity image analysis software (version 6.3;
Perkin Elmer, Waltham, MA, USA) to determine the ratio of green to red
fluorescence (GR), representing Pg and Sg, respectively. Control samples were
used to subtract background levels of auto-fluorescence. Briefly, triplicate samples
of Sg alone were immobilized without Pg or BAR in 12-well culture plates and the
same procedures for dual-species biofilm were followed. Sg-only coverslips were
visualized and images were analyzed using the previously mentioned approach.
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GR background was subtracted using the following formula: GR sample or control
- GR Sg-only. Each treatment group (BAR NPs or free BAR) was analyzed in
triplicate and three independent frames were measured for each well. The mean
and variation (SD) between samples were determined using analysis of variance
(ANOVA) and differences were considered to be statistically significant when p <
0.05. The percent inhibition of Pg adherence was calculated with the following
formula: GR sample/GR control.
Biofilm Disruption Assay
The same procedures utilized in the inhibition assay were followed, except
Pg was allowed to adhere to streptococci in the absence of BAR peptide or BAR
NPs to demonstrate the ability of BAR-encapsulated NPs to disrupt or “treat” preestablished biofilms. The resulting Pg/Sg biofilms were then treated for 3 hr with
free BAR or BAR-encapsulated NPs at various concentrations and processed and
analyzed as described above.
Inhibitory Kinetics of BAR Released from BAR-Encapsulated NPs
Due to the similar release properties of BAR from PLGA and mPEG-PLGA
NPs, PLGA NPs were selected to further assess the ability of NPs to release
therapeutically relevant concentrations of BAR at different time points. PLGA BAR
NPs (1.3 µM) were incubated with gentle agitation in PBS (pH 7.4) at 37°C. After
1, 2, 4 and 8 hr, the NP suspension was centrifuged, and the supernatant was
collected for biofilm experiments. The NPs were re-suspended with new PBS. Pg
was incubated with BAR NP eluate for 30 minutes, and subsequently transferred
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to a well containing an Sg biofilm. The same biofilm inhibition assay procedure
detailed above was used to visualize and analyze the samples.
Time-Dependent Comparison between Free BAR, BAR-Encapsulated, and
BAR Surface-Modified NPs
In addition to delivering high concentrations of BAR during the time frame
of interest, the temporal evaluation of BAR activity against established biofilms was
evaluated and compared. Both BAR-encapsulated and BAR surface-modified NPs
were assessed due to their previously demonstrated efficacy. Pg was allowed to
adhere to streptococci in the absence of peptide, then BAR (3 µM), BARencapsulated, and BAR surface-modified NPs (1.3 and 3 µM) were applied to the
biofilms. The biofilms were assessed 1, 2, and 3 hr post-administration and
visualized as described above.
Results
Nanoparticle Characterization
The morphology, size, and zeta potential of BAR PLGA and mPEG-PLGA
NPs were determined. The morphologies of BAR-encapsulated PLGA and mPEGPLGA NPs are shown in Figure 2.3. Both PLGA and mPEG-PLGA NPs
demonstrated spherical morphology with average unhydrated diameters of 227.5
± 23.0 nm and 243.1 ± 31.2 nm respectively (Table 2.1). In comparison, the
average hydrated diameters of PLGA and mPEG-PLGA NPs were 234.4 ± 19.2
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nm and 278.9 ± 13.8 nm, respectively. PLGA and mPEG-PLGA NPs had zeta
potentials of -13.1± 0.4 mV and -5.9 ± 0.1 mV.
Table 2.1 Physical characterization of NPs

NP Type

Unhydrated
Diameter
(nm)

Hydrated
Diameter
(nm)

Zeta
Potential
(mV)

PLGA NPs

227.5 ± 23.0

234.4 ± 19.2

-13.1 ± 0.4

mPEG-PLGA NPs

243.1 ± 31.2

278.9 ± 13.8

-5.9 ± 0.1

Figure 2.3 SEM images of BAR-encapsulated (A) PLGA NPs and (B) mPEGPLGA NPs. Scale bars represent 1 µm.
Quantification of BAR Loading and Release
The loading of BAR peptide in PLGA and mPEG-PLGA NPs was
determined using fluorescence spectroscopy, and the fluorescence was compared
to a known standard of F-BAR. Loading experiments demonstrated that both PLGA
and mPEG-PLGA NPs highly encapsulated BAR with 19.0 ± 0.1 and 16.1 ± 0.2 µg
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of BAR per mg of NP, respectively, corresponding to encapsulation efficiencies of
44 and 37% (Table 2.2).
Table 2.2 The amount of BAR (µg) loaded in PLGA and mPEG-PLGA NPs (mg).
NP Type

BAR input BAR output
(µg/mg)
(µg/mg)

Encapsulation
Efficiency (%)

PLGA NPs

43

19.0 ± 0.1

44.2

mPEG-PLGA NPs

43

16.1 ± 0.2

37.3

To assess BAR release from the NPs, the fluorescence of supernatant from
1, 2, 4, 8, 24, 48 hr release time points was measured and compared to a known
standard of F-BAR in PBS. Release experiments demonstrated that 47% of
encapsulated BAR (10.3 µg/mg) was released from PLGA NPs, while 56% of BAR
(9.9 µg/mg) was released from mPEG-PLGA NPs within 24 hr (Figure 2.4).
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Figure 2.4 Cumulative release of BAR as a function of mass (µg BAR per mg NP,
open symbols) and percent of total BAR loaded (closed symbols) over 48 hr.
Inhibition (or Prevention) of Pg/Sg Biofilm Formation
BAR-encapsulated PLGA and mPEG-PLGA NPs were functionally
evaluated to determine their potential to inhibit Pg adherence to Sg after 24 hr,
relative to free BAR. As shown in Figure 2.5 and 2.6, Pg adherence was
significantly reduced in the presence of BAR-encapsulated PLGA and mPEGPLGA NPs. Adherence was inhibited by 39% at the lowest administered
concentration (0.3 µM), 59% at 0.7 µM, and reached maximum inhibition (94%) at
the highest concentration of PLGA NPs tested (3 µM). Similar inhibitory results
were observed for mPEG-PLGA NPs, where Pg /Sg biofilm formation was inhibited
by 37%, 55%, and 92% at concentrations of 0.3 µM, 0.7 µM and 3 µM respectively.
The ability of BAR-encapsulated NPs to inhibit biofilm formation was dosedependent (IC50 = 0.70 ± 0.18 µM) with no statistically significant differences
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between PGLA and mPEG-PLGA BAR-encapsulated NPs (p > 0.05). Moreover
these results indicate that a lower concentration of BAR is required if incorporated
within NPs, relative to free BAR administration (IC50 =1.35 ± 0.12 µM) (Figure
2.5).

Figure 2.5 BAR-encapsulated PLGA NPs prevent Pg adherence to Sg. Biofilms
were visualized with confocal microscopy and the ratio of green (Pg) to red (Sg)
fluorescence in z-stack images was determined using Volocity image analysis
software. Each grid represents 21 µm.
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Figure 2.6 BAR-encapsulated mPEG-PLGA NPs prevent Pg adherence to Sg.
Biofilms were visualized with confocal microscopy and the ratio of green (Pg) to
red (Sg) fluorescence in z-stack images was determined using Volocity image
analysis software. Each grid = 21 µm.
Disruption (or Treatment) of Pg/Sg Biofilms
To determine whether BAR peptide is capable of disrupting pre-existing
Pg/Sg biofilms, dual-species biofilms were formed in PBS in the absence of BAR
peptide for 24 hr, and were subsequently incubated for 3 hr with BARencapsulated PLGA or mPEG-PLGA NPs. Various molar concentrations of BAR
NPs ranging from 0.3 to 3 µM were tested. The biofilms were visualized and the
percent inhibition was calculated as described above. As shown in Figure 2.7 and
2.8, BAR-encapsulated PLGA and mPEG-PLGA NPs disrupted pre-existing dual29

species biofilms by ~25% with the lowest administered concentration (0.3 µM),
40% with 0.7 µM, and 85% with 3 µM of BAR-encapsulated PLGA NPs. Similar
trends were observed for the disruption of pre-existing biofilms with 0.3, 0.7, and
3 µM mPEG-PLGA NPs (20%, 38%, and 80% disrupted). Overall the IC50 values
of PLGA and mPEG-PLGA (1.35 ± 0.12 µM) NPs for biofilm disruption were not
statistically significant (p > 0.05, Figure 2.9); demonstrating statistically significant
improvements in efficacy relative to free BAR (p < 0.05).

Figure 2.7 BAR-encapsulated PLGA NPs disrupt pre-established Pg-Sg biofilms.
Biofilms were visualized with confocal microscopy and the ratio of green (Pg) to
red (Sg) fluorescence in z-stack images was determined using Volocity image
analysis software. Each grid represents 21 µm.
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Figure 2.8 BAR-encapsulated mPEG-PLGA NPs disrupt pre-established Pg-Sg
biofilms. Biofilms were visualized with confocal microscopy and the ratio of green
(Pg) to red (Sg) fluorescence in z-stack images was determined using Volocity
image analysis software. Each grid = 21 µm.
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Figure 2.9 Comparison of the concentration of BAR-encapsulated PLGA and
mPEG-PLGA NPs needed to (A) inhibit or (B) disrupt Pg/Sg biofilms.
Inhibitory Activity of BAR Released from BAR-Encapsulated NPs
To determine the inhibitory potential of BAR-encapsulated NPs, as a
function of release duration, streptococcal cells were immobilized and Pg was
incubated with eluate released from 1.3 µM BAR-encapsulated PLGA NPs at 1, 2,
4, and 8 hr. BAR-encapsulated PLGA NPs were selected due to their similar
release and inhibitory properties, relative to mPEG-PLGA NPs. As shown in
Figure 2.10, BAR released during the first two hours, inhibited biofilm formation
(68% and 32%, respectively) when compared to the control untreated biofilm,
whereas BAR released after 4 and 8 hr provided less inhibitory activity against
biofilm formation (25% for both time points). These results indicate that BARencapsulated NPs release an inhibitory dose of peptide for at least 2 hr.
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Figure 2.10 BAR-encapsulated PLGA NPs inhibit Pg adherence to Sg after
different durations of release. Biofilms were visualized with confocal microscopy
and the ratio of green (Pg) to red (Sg) fluorescence in z-stack images was
determined using Volocity software. Each grid = 21 µm.
Time-Dependent Comparison of Free BAR, BAR-Encapsulated, and BAR
Surface-Modified NP Biofilm Disruption
Previous studies demonstrated that BAR surface-modified PLGA NPs
potently disrupt pre-established Pg/Sg biofilms95. To compare the temporal effect
resulting from the administration of the newly formulated BAR-encapsulated NPs,
relative to free BAR or previously tested BAR surface-modified NPs, two
concentrations of BAR-encapsulated and BAR surface-modified PLGA NPs were
compared with free BAR after 1, 2, and 3 hr administration to pre-established
biofilms. As shown in Table 2.3 and Figure 2.11, free BAR (3 µM) minimally
disrupted pre-existing biofilms during the first hour of application (23%), and
33

demonstrated a slight increase in disruption after two hours (44%). After 3 hr, free
BAR (3 µM) disrupted 69% of the pre-existing biofilm. In comparison,
administration of the same equimolar concentration of BAR-encapsulated NPs (1.3
and 3 µM) disrupted the established biofilm during the first hour of exposure by
32% and 38%, respectively and demonstrated even more potent disruption (47%
and 52%) after two hours. The maximum disruption for 1.3 and 3 µM doses (66%
and 77%, respectively) was achieved after 3 hr exposure to biofilms.
Comparatively, both 1.3 and 3 µM BAR surface-modified NPs disrupted preexisting biofilms within one hour by 43% and 49%, respectively, and induced more
potent biofilm disruption (59% and 69%) after 2 hr exposure, demonstrating
statistically significant disruption, relative to disruption induced by free BAR
peptide. The highest levels of disruption (71% and 83% respectively) were
achieved after 3 hr BAR surface-modified NP administration. Overall, BAR surfacemodified NPs were statistically more effective than free BAR (p <0.05) in disrupting
established biofilms after 1, 2, and 3 hr administration. However, no statistical
differences were observed for BAR-encapsulated NPs (p > 0.05), relative to BAR
surface-modified NPs or free BAR peptide after 1, 2, or 3 hr administrations.
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Figure 2.11 Disruption of established Pg/Sg biofilms after different exposure times
to BAR surface-modified NPs, BAR-encapsulated NPs and free BAR. Biofilms
were visualized with confocal microscopy and the ratio of green (Pg) to red (Sg)
fluorescence in z-stack images was determined using Volocity software. Each grid
= 21 µm.
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Table 2.3 Percent disruption of established biofilms with different treatment
groups.
% Disruption of Pre-Formed Biofilms

Time
(Hr)

Free BAR
(3 µM)

BAR-mod
NPs (1.3 µM)

BAR-mod
NPs (3 µM)

BAR-encap
NPs (1.3 µM)

BAR-encap
NPs (3 µM)

1

22.6 ± 0.2

43.4 ± 0.2

48.9 ± 0.1

32.3 ± 0.1

37.7 ± 0.1

2

44.4 ± 0.2

59.2 ± 0.1

68.7 ± 0.1

46.6 ± 0.2

52.4 ± 0.2

3

69.0 ± 0.0

71.2 ± 0.1

83.4 ± 0.0

66.1 ± 0.1

77.0 ± 0.0

Discussion
Porphyromonas gingivalis has been identified as a “keystone” pathogen
involved in the initiation and progression of periodontal inflammatory disease, by
disrupting host-microbe homeostasis and inducing population changes in the
subgingival biofilm. This disruption and colonization is initially prompted by the
association of Pg with oral streptococci in the supragingival niche, and is thus an
ideal target for therapeutic intervention9. Previous studies have shown that BAR
peptide inhibits biofilm formation by Pg and Sg in vitro and reduces the virulence
of Pg in a murine model of infection15,17. While efficacious, BAR effectiveness was
limited by the duration of exposure within the oral cavity, and necessitated a higher
concentration to disrupt previously established biofilms15, 17. In previous work we
sought to address these challenges by synthesizing BAR surface-modified NPs to
multivalently inhibit biofilm formation95. The goal of this study was to develop,
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characterize, and compare BAR-encapsulated NPs that release BAR within a time
frame relevant to delivery in the oral cavity.
Nanoparticle characterization revealed that PLGA and mPEG-PLGA BARencapsulated NPs exhibited spherical morphologies and average particle
diameters of 234.4 ± 19.2 nm and 278.9 ± 13.8 nm, with respective zeta potentials
of -13.1 ± 0.4 mV and -5.9 ± 0.1 mV. These values are in agreement with expected
values for these polymeric NPs89,120. Both PLGA and mPEG-PLGA NPs were
synthesized with 43 µg of BAR per mg NP, corresponding to loading
concentrations deemed feasible for biofilm inhibition with free BAR 111-113. PLGA
and mPEG-PLGA NPs demonstrated relatively high peptide loading with 19.0 ±
0.1 and 16.1 ± 0.2 µg BAR per mg of NP respectively.
In addition to high loading, PLGA and mPEG-PLGA NPs released 40% and
48% of BAR within the first 4 hr, with no statistically significant differences between
release profiles. The NP formulations were designed to achieve therapeutic
concentrations of BAR in the oral cavity for a minimum of 2 hr. This initial window
of 2 hr release was targeted as we envision formulating NPs in a mouth rinse or
toothpaste product. Ideally, in future formulations, we seek to tailor the release of
peptide for up to 12 hr since we envision these formulations may be applied once
or twice daily, to exert immediate effect over a number of hours.
To assess the functionality of BAR-NPs, the inhibition and disruption
concentrations of BAR-encapsulated PLGA and mPEG-PLGA NPs were
determined against dual-species biofilms. As shown in Figures 2.5 through 2.8,
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BAR NPs demonstrated potent inhibition and disruption with IC50s = 0.7 µM and
1.3 µM, respectively, with negligible differences observed between PLGA and
mPEG-PLGA NPs. To explore the temporal effect of BAR released from PLGA
NPs on biofilm inhibition (prevention) in greater depth, the efficacy of BARencapsulated NPs was assessed in a dual-species biofilm after 1, 2, 4 and 8 hr
post-application. Sufficient BAR release was achieved, relating to inhibitory
concentrations of 1.3 µM during the first 4 hr of administration (Figure 2.10).
Moreover, the temporal dependence of free BAR, BAR-encapsulated, and BAR
surface-modified NPs to disrupt pre-established biofilms (treatment) was
measured after 1, 2, and 3 hr application. As shown in Figure 2.11 and Table 2.3,
BAR-encapsulated and BAR surface-modified NPs achieved moderate biofilm
inhibition within 1 hr in a dose-dependent manner; however, similar concentrations
of free BAR required prolonged exposure of up to 3 hr to achieve more potent
effect. These results demonstrate that BAR-encapsulated NPs provide a feasible
alternative to free BAR and BAR surface-modified NPs to target dual-species oral
biofilms and provide rapid onset of action. Together, these studies indicate that
BAR-encapsulated NPs may serve as a short-term delivery formulation to enhance
BAR delivery and potency in the oral cavity. Moreover, by encapsulating versus
surface-modifying NPs with BAR, these NPs may offer the potential to specifically
target NPs with modifications that can complement BAR activity to engage with
these or other bacterial species in future work.
To date, a variety of polymeric nanoparticle formulations have been
developed for oral delivery; however, these vehicles have primarily focused on the
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delivery of non-specific active agents such as antibiotics86,90,91,94,123-128. Antibiotics
such as chlorhexidine123,124, minocycline86,94, clarithromycin126, vancomycin125,
doxycycline127, and tetracycline90,91,128 are among the antibiotics that have been
incorporated into a variety of polymeric vehicles86,90,94,124-127 to provide sustaineddelivery, prolong activity, exert antibacterial activity, and decrease antibiotic
cytotoxicity86,90,94,124-127. Yet, despite antibiotic choice, primary concerns of
antibacterial resistance and cytotoxicity remain90,123,124. While chitosan and PLGA
NPs that encapsulated chlorhexidine dihydrochloride (CHX) demonstrated strong
adherence to tooth surfaces and sustained-release for 48 hr in neutral pH
conditions, moderate cytotoxicity due to CHX was observed in human gingival
fibroblasts124. Similar studies seeking to ameliorate periodontal infection caused
by A. actinomycetemcomitans and P. nigrescens with PLGA lovastatin-chitosantetracycline NPs demonstrated potent inhibition up to one week after
administration. However, significantly elevated alkaline phosphatase was
observed in cells treated with 0.1% or 0.3% tetracycline-loaded nanoparticles on
days 7 and 990. Overall, these studies have shown that delivery vehicles have the
potential to increase antibiotic effectiveness by decreasing the concentration
required. However, bacterial resistance, non-specific targeting, and cytotoxicity
concerns with chronic use suggest that the development of more specifically acting
active agents will offer safer alternatives for biofilm inhibition.
More recently, specifically targeted biological agents have been
investigated to treat periodontal diseases. Delivery of thyA gene129, Punica
granatum extract130, H. madagascariensis leaf extract131, miR-146a132, and the
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anti-inflammatory agent 15d-PGJ2133 have been investigated to vaccinate against
and target periodontal diseases. Recent work assessed the delivery of an oral
vaccine comprised of an auxotrophic complementation of the thyA gene to
produce an immune response against Sg. Although this study demonstrated
promise utilizing Sg as a live oral vaccine, to date there are few formulations
available to localize or sustain biologic administration to the oral cavity129. In other
work, PLGA NPs encapsulating a novel anti-inflammatory agent (15d-PGJ2),
demonstrated promise in reducing inflammatory response and bone resorption in
mouse model of periodontitis after daily administration 133, demonstrating the
feasibility of combined biologic and delivery vehicle against oral pathogens.
Despite this recent progress in the delivery of biological agents for oral
applications, currently few biological agents in combination with delivery vehicles
have been developed to inhibit keystone-specific interactions during the initial
stages of periodontal disease95.
In addition to progress in the development of vehicles to encapsulate
antibiotic and biological agents in polymeric delivery vehicles, polymeric platforms
have also been surface-modified with a variety of molecules including RGD94,
chitosan124,126, tertiary amines bearing two t-cinnamaldehyde substituents134,
dimethyl-octyl ammonium134, and BAR peptide95 to increase the mucoadhesivity
(and in the latter case, specificity) of oral delivery formulations.
A variety of polymers have been modified with biological ligands to impart
enhanced therapeutic effect94,95.

As one example, the delivery of antibiotic
40

minocycline-loaded

poly(ethylene

glycol)–poly(lactic

acid)

(PEG–PLA)

nanoparticles have targeted oral epithelial cells by surface-modification with RGD
peptides. Surface-modification of PEG-PLA NPs increased epithelial cell
attachment and maintained effective drug concentrations in gingival fluid for more
than two weeks in vivo, relative to unmodified minocycline NPs. Similarly, chitosanmodified polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft
copolymer (Soluplus) and poly-(DL-lactide-co-glycolide) nanoparticles loaded with
clarithromycin, increased antibacterial efficacy and provided sustained-release
against oral biofilms126. Although this study demonstrated effective treatment of
periodontitis, the limitations of antibiotic delivery still pose challenges 94. Surface
modification of nanoparticles has imparted new attributes to target active agents
to oral-specific niches. We expect that combining our current work, with surface
functionalization demonstrated in our previous study95, may confer additional
advantages in targeting keystone species by providing prevention and treatment
via adhesion and a localized release-mediated platform.
Taken together, our results demonstrate that BAR-encapsulated NPs
achieve more potent inhibition and disruption than equimolar free BAR
administration. We believe that incorporation of BAR peptide in NPs provides
gradual release of BAR peptide, while BAR-modification offers a platform to
provide a higher localized concentration of BAR in the oral cavity via multivalent
interactions. BAR-encapsulated NPs offer a platform to improve efficacy, and
potentially longevity in the oral cavity compared to the transient activity of free
BAR. These experimental results will be helpful in developing NPs in therapeutic
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formulations such as toothpaste, mouth rinse or chewing gum. Future studies may
focus on developing blended polymeric NPs to more gradually release inhibitory
concentrations for 8-12 hr. Moreover, combining this platform with surface
functionality to provide mucoadhesive or specific interactions with gingival tissue
may be pursued to enhance the targeting potential. Ongoing and future work in our
groups seeks to assess the efficacy of both BAR-modified and BAR-encapsulated
NPs in a murine model of periodontitis.
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CHAPTER 3
FUNCTIONAL ASSESSMENT OF PEPTIDE-MODIFIED PLGA
NANOPARTICLES AGAINST ORAL BIOFILMS IN A MURINE MODEL OF
PERIODONTITIS
Introduction
The most common and currently employed periodontal treatments consist
of physical methods such as scaling and root planing to remove the oral biofilm,
followed by antibiotic therapy. However, variation in patient response and the
immediate reformation of the oral biofilm post-removal can promote disease
recurrence. In addition to the challenges associated with mechanical debridement,
the administration of local and systemic antibiotics can enhance opportunistic
fungal infections, potential allergic reactions, or the emergence of antibacterial
resistant species. Moreover, current antibiotics may non-specifically disrupt
microbial homeostasis by killing commensal organisms, and often high, frequently
administered doses are required to penetrate periodontal biofilms 35,37,107. Given
these challenges, the development of more specific agents targeting periodontal
pathogens has the potential to offer safer and more effective alternatives against
oral biofilms.
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While several studies have investigated natural and synthetic biologics
against oral inflammation and biofilms, including Punica granatum extract 130 H.
madagascariensis leaf extract131, miR-146a132, and the anti-inflammatory agent
15d-PGJ2133, our approach has been to target the specific interaction between Pg
and oral streptococci that contributes to the initial colonization of the oral cavity
leading to the development of periodontal disease111.
Previous work in our group has shown that Pg adherence to streptococci is
driven by the interaction of the minor fimbrial antigen (Mfa) of Pg with streptococcal
antigen (e.g., SspB) I/II (AgI/II)109,110. SspB polypeptide is a multifunctional surface
protein of Sgi and is a member of antigen I/II complex that is expressed by nearly
all streptococci that inhabit the oral cavity. SspB is 1,500 residues in length and
includes seven structural domains that are effectively maintained in all antigen I/II
polypeptides. Previous studies in our group have shown that the region
encompassing residues 1167 to 1250 of SspB (designated BAR) was required for
the in vitro adherence of Pg to Sg cells. From these studies, a peptide (designated
BAR), was developed that potently inhibited Pg adherence to streptococci in vitro
and reduced Pg virulence in a mouse model of periodontitis. However, while BAR
inhibited the initial formation of Pg/streptococcal biofilms, much higher
concentrations of peptide were required to disrupt an established biofilm. In
addition, disruption of more complex three-species biofilms containing a bridging
organism such as Fusobacterium nucleatum also required higher concentration
and prolonged exposure to BAR.
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Currently, a variety of localized delivery approaches, including gels,
implants, fibers, and films are used to deliver antibiotics. These formulations are
often administered following the scaling process to retain antibiotics for prolonged
duration in periodontal pockets. However, non-degradable implants such as nylon
fibers135, and acrylic and ethyl cellulose strips136,137 require surgical removal, while
burst release of active agents is often observed after the administration of films
and gels94,138. Recently, polymeric nanoparticles have been investigated as a
potential alternative to deliver active agents, due to their proven safety and
biocompatibility. Moreover, in contrast to the ubiquitous activity of metallic NPs
with inherent antimicrobial efficiency139,140, FDA-approved polymers such as
poly(lactic-co-glycolic) acid (PLGA), have demonstrated biocompatibility and
flexible tuning of physical properties, enabling tailored drug release and favorable
dosing profiles115. In addition, polymer NPs have the ability to impart
mucoadhesive properties due to the electrostatic interactions between NPs and
gingival epithelium114-116. While a variety of polymer types can promote
mucoadhesion, NPs synthesized from commonly used polymers, such as PLGA,
may achieve mucoadhesion via hydrogen bonding, polymer entanglement with
mucins, hydrophobic interactions, or a combination of these mechanisms 141,142.
Furthermore, NP transport and internalization through the epithelium is dependent
on particle size, surface charge, polymer hydrophobicity, mucoadhesivity, and the
presence or absence of surface ligands like chitosan or PEG 116,132,141. From a
fabrication perspective, PLGA NPs are easily synthesized and provide long lasting
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formulations that can protect active agents, especially more labile biological
agents, thereby maintaining their functional activity.
Given the attributes of PLGA NPs, we sought to address some of the
delivery challenges confronting free BAR, including the relatively transient
inhibition of Pg in the oral cavity and higher localized doses of BAR required to
disrupt established biofilm111-113,143. Multivalency is one option to improve the
binding of BAR by enhancing the avidity and decreasing the detachment rate from
Pg95,144,145. Previous studies have demonstrated that multivalently targeted NPs
can improve binding, increase localized concentration and decrease the effective
therapeutic doses and frequencies94,95,121,134,146. Previous work from our groups
demonstrated that BAR-modified NPs (BAR-NPs) delivered a high localized
concentration of BAR peptide and improved the in vitro effectiveness of BAR
through multivalent interactions with Pg, relative to free BAR95. Thus, we
hypothesized that conjugating BAR to the NP surface may similarly decrease the
therapeutic dose of BAR required to inhibit biofilm formation in vivo through
multivalent binding to Pg, more effectively inhibiting oral biofilm formation95,134. For
oral administration, we administrated free BAR and BAR-modified NP with 2%
carboxymethylcellulose to test BAR-NPs against the “best” case adhesive
formulations to improve retention in the oral cavity and to target Pg. In future work,
we propose to incorporate BAR-NPs in a mouthwash or gel formulation to be
applied twice daily. Here our goal was to advance our previous in vitro work to
assess the in vivo efficacy and safety of BAR-modified NPs in a murine model of
periodontitis and in gingival and erythrocytic cell lines.
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Materials and Methods
Peptide Synthesis
BAR peptide is comprised of residues 1167 to 1193 of the SspB (Antigen
I/II) protein of Sg with the sequence NH2-LEAAPKKVQDLLKKANITVKGAFQLFSCOOH112. To facilitate conjugation of BAR to the NP surface, the peptide was
synthesized with an N-terminal biotin. Biotinylated BAR was subsequently
attached to NPs that had been modified with palmitylated avidin. To enable peptide
quantification and detection, some preparations of BAR were modified such that
the epsilon amine of the underlined lysine residue of BAR was covalently reacted
with 6-carboxyfluorescein to produce fluorescent BAR (F-BAR). All preparations of
peptides were synthesized by BioSynthesis, Inc. (Lewisville, TX) and were
guaranteed to have greater than 90% purity via RP-HPLC analysis.
BAR Surface-Modified Nanoparticle Synthesis
BAR surface-modified NPs were synthesized using a previously described
single-emulsion technique88,121. PLGA with a 50:50 monomer ratio and 0.55–
0.75 dL/g inherent viscosity, was purchased from LACTEL®. Briefly, 100 mg PLGA
was dissolved in 2 mL dichloromethane (DCM) overnight. The following day, 2 mL
of a 5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 mL of 5 mg/mL
avidin-palmitate. The 2 mL PLGA/DCM solution was added dropwise to 4 mL
PVA/avidin-palmitate solution while vortexing. The NP solution was added to 50
mL of 0.3% PVA for 3 hr to evaporate residual DCM. After evaporation, the NP
solution was centrifuged at 13,000 rpm (20,442 x g) at 4°C. Supernatant was
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discarded, and the pelleted NPs were resuspended in 10 mL phosphate buffered
saline (PBS) for 30 min on a benchtop rotator, with biotinylated BAR peptide at a
molar ratio of 6:1 BAR:avidin (18 nmol/mg) in PBS. After conjugation, the NPs were
washed two times with deionized water (diH2O) by centrifugation at 13,000 rpm
(20,442 x g) at 4°C to obtain NPs with sizes less than ~200 nm. After washing,
BAR surface-modified NPs were suspended in 5 mL of diH2O, frozen at -80°C,
and lyophilized.

F-BAR-modified NPs were synthesized similarly, but were

protected from light during synthesis.
NP Characterization: NP Morphology, Size, BAR Conjugation
Unhydrated NP morphology, diameter, and size distribution were
determined using scanning electron microscopy (SEM) (XL-30 ESEM-FEG SEM,
FEI Company, USA). Lyophilized NPs were mounted on carbon tape and sputter
coated with a thin layer of gold/palladium. Average diameters of 500 particles were
determined from SEM images (n=3) using image analysis software (ImageJ,
National Institutes of Health, version 1.5a, ImageJ.nih.gov). Dynamic light
scattering and zeta potential analyses were performed to determine the
hydrodynamic diameter and surface charge of hydrated NPs. The unhydrated and
hydrated diameters of NPs are typically assessed to establish the size
characteristics within different conditions of dry storage and more physiologically
relevant aqueous environments. Briefly, a 1 mg/mL sample of BAR-modified PLGA
NPs in diH2O was prepared. After vortexing and sonication, samples were diluted
at a 1:50 ratio in diH2O. One mL was aliquoted to the cuvette for analysis [Malvern,
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Malvern, UK (Zetasizer Nano ZS90), courtesy of Dr. Martin O’Toole, Univ. of
Louisville] to measure dynamic light scattering and zeta potential with Zetasizer
Nano software. Samples were run in triplicate, using a refractive index of 1.57 for
PLGA, absorption coefficient of 1, and water refractive index of 1.33. The
equations used by the Zetasizer to calculate nanoparticle size are shown in
Supplementary Data.
To measure the amount of BAR peptide that was conjugated to the NP
surface, a fluorescence binding assay was conducted with F-BAR NPs. After
conjugation, NPs were centrifuged and washed twice with diH2O to remove
unbound BAR from the formulated NPs. NPs were then suspended in 1X PBS to
create a 1 mg/mL NP solution and the resulting samples were transferred to a
microtiter plate in triplicate. Total NP-associated fluorescence was determined
using Victor3 Multilabel spectrophotometer (488/518 nm excitation/emission), and
peptide quantity was determined from a standard curve of known F-BAR
concentrations95. The stability of the avidin palmitate interaction with the NP
surface has been previously tested by assessing the release of avidin and
biotinylated ligand from the NP surface with respect to time 146,147. In addition, the
functional stability of BAR-NPs was tested through in vitro inhibition assays against
biofilms prior to these in vivo experiments95.
Growth of Bacterial Strains
Pg (ATCC 33277) was grown in Trypticase soy broth (Difco Laboratories
Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL
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menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently
inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aerobically without shaking in brain-heart infusion broth (Difco Laboratories Inc.)
supplemented with 1% yeast extract for 16 hr at 37°C111-113.
In Vivo Model of Periodontitis
The protocols used for the study were approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Louisville, as described in
the federal guidelines for the care and use of laboratory animals. Ten weeks-old
specific-pathogen-free BALB/cByJ mice were obtained from the Jackson
Laboratory (Bar Harbor, ME) and housed in the University of Louisville Research
Resource Center animal facility. The mice were fed with Lab Diet 5001 meal
(Purina Mills, LLC, Gray Summit, MO) during the entire experiment.
The oral infection of mice was performed as previously described 113. A total
of 8 mice per group were used per experiment. Animals were initially treated with
sulfamethoxazole (MP Biomedical, Solon, OH) at a final concentration of (800
µg/mL) and trimethoprim (Sigma, St. Louis, MO) at a final concentration of (400
µg/mL) ad libitum for 10 days, every two days. Four days after the last antibiotic
treatment, all groups of mice with the exception of the sham-infected control group
were orally infected with 109 CFU of Sg cells suspended in 1 mL of 2%
carboxymethylcellulose (CMC; MP Biomedical, Solon, OH) in sterile PBS using a
2.25 mm feeding needle (Popper and Sons, Inc., New Hyde Park, NY). Sg was
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administered five times in total, every two days. Sham-infected animals received
CMC without bacteria. Following confirmation of Sg colonization by PCR, two
groups of animals were infected five times with 10 7 CFU of Pg in CMC containing
BAR (0.7 and 3.4 µM) at two day intervals and another group was infected five
times with 107 CFU of Pg in CMC containing BAR-NPs (BAR concentration = 0.7
µM) at two day intervals. Two additional groups of animals were infected either
with Pg alone or Sg alone. After the infection process, all animals were
subsequently rested for 47 days with daily observation to record death or sickness
and then euthanized via CO2 asphyxiation.
Infection Confirmation
Sg and Pg colonization were confirmed by collecting oral samples from the
gingiva of the upper molars using a 15 cm sterile polyester-tipped applicator
(Puritan Medical Products Co., Guilford, ME), 14 days after the last oral infection.
Samples were then added to 10 mL of brain-heart infusion broth (Difco
Laboratories Inc.) for streptococcal species enrichment and trypticase soy broth
(Difco Laboratories Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast
extract, 1 µg/mL menadione, and 5 µg/mL hemin to select for Pg. Samples were
incubated at 37°C for 24 hr under anaerobic conditions. The resulting cells were
identified by PCR using Sg- and Pg-specific primers113.

51

Determination of Maxillary Alveolar Bone Loss
Mouse skulls were autoclaved for 15 min to remove skin and muscles, and
were subsequently soaked in 3% hydrogen peroxide overnight at room
temperature to remove remaining muscle. Skulls were washed with diH2O and
cleaned with a 1% bleach solution for 30 s, sonicated at 14 V for 1 min, and washed
again with diH2O. To confirm skull cleaning, toothpaste was applied and brushed
away, followed by immersion in a 1% bleach solution for 30 s and sonication (14
V). To stain the skulls, skulls were immersed in 1% methylene blue for 15 s and
rinsed with DI water to remove excess dye. The stained skulls were air-dried prior
to alveolar bone loss measurements. Bone loss was assessed by measuring the
distance between the alveolar bone crest (ABC) and the cemento-enamel junction
(CEJ) at 7 sites on the buccal side of the right and left maxillary molars for a total
of 14 measurements. This was accomplished using a dissecting microscope fitted
with a video imaging marker measurement system (model VIA-170K; Fryer) at a
total magnification of 40x113. Measurements were taken in millimeters. The
average of the total bone loss for each mouse group was assessed and subtracted
from the baseline bone loss observed in sham-infected mice. Statistical differences
in bone loss were analyzed by ANOVA after passing Bartlett's and Brown-Forsythe
tests for homogeneity of variances using GraphPad InStat (La Jolla, CA). A pairwise, parametric analysis of variance using a Bonferroni multiple comparison posttest was used to determine the statistical difference among the individual mouse
groups. A P value of ≤ 0.05 was considered to be statistically significant.
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Histological Analysis
Samples of maxillary molar regions were dissected from each mouse, and
then fixed in 4% paraformaldehyde overnight. Periodontal tissues were dehydrated
by passing through ascending concentrations of ethanol then cleared in xylene
and embedded in paraffin. Serial sections (5-6 μm) were cut and mounted on glass
slides (Sigma, St. Louis, MO). Microscopic examination for slides was carried out
after hematoxylin and eosin staining148.
Immunofluorescence Assay
An immunofluorescence assay was used to assess IL-17 expression in
gingival sections. Tissue sections, 5-6 μm in thickness, were mounted on glass
slides. Tissue sections were deparaffinized by immersion in xylol two times for 15
min each, and rehydrated in absolute, 95% and 70% ethanol. Excess ethanol was
removed then slides were placed in water. Antigen IL-17 was recovered by
microwave heating in water and non-specific binding was blocked with 5% bovine
serum albumin for 1 hr. Then, slides were incubated for 24 hr at 4˚C with IL-17A
monoclonal antibody AlexaFluor 488 (eBioscience™), examined via confocal
microscopy, and IL-17 immunofluorescence was quantified using Volocity
software149.
Tissue Culture
Telomerase immortalized gingival keratinocytes (TIGKs) were grown on 24well collagen-coated plates (Becton Dickinson, Bedford, MA) and cultured using
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penicillin/streptomycin (100 U/mL final concentration; St. Louis, MO), recombinant
human (rh) insulin (5 µg/mL), L-glutamine (6 mM), epinephrine (1 µM), apotransferrin (5 µg/mL), rh TGF-α (0.5 ng/ mL), extract PTM, hydrocortisone
hemisuccinate (100 ng/mL), and calcium chloride (0.06 mM). The epithelial cells
were incubated at 37°C in the presence of 5% CO2 for 6 days until they reached
95% confluence. The cells were washed and administered media without
antibiotics during toxicity testing.
Determination of BAR and BAR-NP In Vitro Cytotoxicity
Hemolytic Assay: A total of 250 µL of 1% sheep erythrocytes (Rockland Inc,
Pennsylvania, USA) was suspended in sterile PBS containing 5% fetal bovine
serum (FBS buffer). BAR-NPs or free BAR peptide were suspended in FBS at
concentrations of 1.3 and 3.4 µM (the maximum concentrations used in in vitro and
in vivo studies) and were added to the erythrocyte suspension. The mixtures were
incubated at 37°C for 3 hr. After centrifugation (3,500 x g), hemoglobin released
due to cell lysis was analyzed by spectrophotometry at 541 nm. A positive control
group was run in which PBS was replaced with diH2O.
MTT Assay: TIGK cells were seeded in 12-well plates at a density of 6 x 104 cells
in 1 mL media per well, and incubated for 24 hr to allow for 60–70% confluency
and sufficient adhesion. Cells were treated with 1.3 or 3.4 µM of free BAR or BARNPs. After 24 hr, 100 µL of MTT solution (10% of total volume) was added to the
media of all samples. The solution was incubated at 37°C for 4 hr. After this period,
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550 µL of lysis buffer (50% of total volume) was added to the media of each well
and plates were incubated for overnight. The absorbance of each well was read at
570 nm, and the sample absorbance was normalized to the absorbance of
untreated cells (media only). Treatment with 10% DMSO media (100 µL DMSO in
900 µL media) was used as a positive control for cell death.
ATP Assay: Total ATP levels in cell culture were assessed by using the CellTiterGlo reagent (Promega, Madison WI), as described by the manufacturer. TIGK cells
were seeded at a density of 6 x 104 cells in 1 mL media per well and incubated at
37°C, 5% CO2 for 24 hr in a 12-well flat bottom plate. Cells were then incubated
with free BAR or BAR-NPs (1.3 or 3.4 µM) for 24 hr at 37°C in 5% CO2. Cells were
then lysed with 500 µL of 0.1% Triton X-100 for 30 min at 37°C. The lysates were
collected and centrifuged at 1,000 x g for 10 min at 4°C, and 50 µL of supernatant
was mixed with 50 µL of CellTiter-Glo reagent. Samples were incubated at ambient
temperature for 10 min in a black 96-well plate in the dark. Total luminescence was
measured with a Victor 3 luminometer (Perkin-Elmer, Inc). Cells incubated with 1
ng of staurosporine or with medium only served as positive and negative controls
for cell death, respectively.
LDH Assay: Cell membrane leakage was measured by the release of lactate
dehydrogenase (LDH). Extracellular LDH was quantified using a CytoTox96® nonradioactive cytotoxicity assay (Promega, Madison WI) as described by the
manufacturer. TIGK cells were plated at density of 6 x 104 cells in 1 mL media per
well in a 12-well flat bottom plate, and incubated at 37°C, 5% CO2 for 24 hr. Free
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BAR or BAR-NPs (1.3 or 3.4 µM) were added to cells in triplicate for 24 hr at 37°C
in 5% CO2. Fifty microliters of supernatant from free BAR and BAR-NP-treated (1.3
and 3.4 µM) cells were added to the LDH substrate and incubated at room
temperature for 30 min. The reactions were subsequently terminated by adding 50
µL of stop solution. LDH activity was determined by measuring the optical density
of the solution at 490 nm. Cells treated with staurosporine or with medium only
served as positive and negative controls for cell death, respectively.
Apoptosis: The degree to which free BAR or BAR-NPs (1.3 or 3.4 µM) induced
apoptosis in TIGK cells was determined using the PE Annexin V/Dead Cell
Apoptosis Kit with SYTOX® Green for Flow cytometry (Invitrogen). TIGK cells
were cultured in 12-well microtiter plates with an initial density 2 x 10 5 cells in 1.5
ml media. After 24 hr at 37°C, the medium was decanted, replaced with fresh
medium containing the desired concentration of BAR or BAR-NPs and incubated
for an additional 18 hr.

The cells were washed with PBS, trypsinized and

centrifuged at 250 x g. The cell pellet was suspended in 100 µL of binding buffer
supplemented with 1 µL Sytox and 5 µL Annexin florescent dye and incubated for
15 min at 37°C. Samples were then diluted by addition of 400 µL binding buffer
and analyzed by flow cytometry using a FACScalibur flow cytometer (Becton
Dickinson), measuring the fluorescence emission at 530 nm and 575 nm. Cells
treated with 2 mM hydrogen peroxide or medium only for 4 hr at 37°C and 5% CO2,
served as positive and negative controls for apoptosis.
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Statistical analysis
Data from each of the toxicity tests and IL-17 ELISA were analyzed using ANOVA
after passing Bartlett's and Brown-Forsythe tests for homogeneity of variances
using GraphPad InStat (La Jolla, CA). A pair-wise, parametric analysis of variance
using a Bonferroni multiple comparison post-test was used to determine the
statistical difference among the individual groups. A P-value of ≤ 0.05 was
considered to be statistically significant.
Results
Nanoparticle Characterization
The morphology of BAR-NPs, relative to unmodified NPs, is shown in
Figure 3.1. BAR-NPs demonstrated a spherical morphology without any observed
changes resulting from conjugation with BAR peptide. The average unhydrated
diameters of BAR-NPs and unmodified NPs measured from SEM images were
87.9 ± 29.4 nm and 155.8 ± 37.6 nm, respectively. In comparison, the average
hydrated diameters of BAR-NPs and unmodified NPs, as measured with dynamic
light scattering (Malvern Zetasizer) were 333.8 ± 17.8 nm and 312.6 ± 11.2,
respectively. This is in agreement with previous data demonstrating that BAR-NP
hydrated diameters were higher than unhydrated diameters

95.

The addition of

positively charge avidin and subsequent conjugation with BAR increased the
overall charge of BAR-NPs to -10.3 ± 0.9 mV, relative to unmodified PLGA NPs (22.6 ± 1.2 mV), demonstrating BAR conjugation to the PLGA NP surface (Table
3.1).
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Table 3.1 Physical characterization of NP diameter and surface charge. Data
represent the mean ± standard deviation of at least 3 independent samples.
NP Type

Unhydrated
Diameter (nm)

Hydrated
Diameter (nm)

Zeta Potential
(mV)

BAR-Modified PLGA
NPs

87.9 ± 29.4

333.8 ± 17.8

-10.3 ± 0.9

Unmodified PLGA NPs

155.87± 37.6

312.6 ± 11.2

-22.6 ± 1.2

Figure 3.1 SEM images of (A) BAR-modified PLGA NPs and (B) Unmodified PLGA
NPs. Scale bar represents 1 µm. Images are representative of a minimum of 3
independent samples, with n > 500 NPs assessed in total.
Quantification of BAR Conjugation
The amount of BAR peptide conjugated to PLGA NPs was determined using
fluorescence spectroscopy, and the fluorescence was compared to a known
standard of F-BAR. Previous work in our groups has shown that 3 nmol avidin
conjugated per mg of PLGA NPs and avidin has four binding sites, with the
potential to bind 12 nmol of BAR, if all avidin sites were available95,146,150. Loading
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experiments demonstrated that 7.1 nmol of BAR were bound per mg of PLGA NPs
(corresponding to 9024 BAR ligands/mg of NP), with a conjugation efficiency 40%.
Alveolar Bone Loss
The effectiveness of free BAR and BAR-NPs to inhibit Pg virulence was
evaluated by measuring Pg-induced alveolar bone loss. Microscopic images of the
maxilla of sham-infected, Pg/Sg infected, free BAR and BAR-NP-treated mice are
shown in Figure 3.2. Quantification of alveolar bone loss showed that mice that
were infected with both Sg and Pg exhibited significantly (P ≤ 0.0001) increased
bone loss (-1.37 ± 0.31 mm), relative to uninfected mice or animals infected with
Sg-only (-0.33 ± 0.07 mm) or Pg-only (-0.44 ± 0.025 mm). Mice that were infected
with both Sg and Pg and treated with 0.7 or 3.4 µM free BAR exhibited a significant
reduction in bone loss (-0.69 ± 0.1 mm and -0.56 ± 0.09 mm, respectively), relative
to infected untreated animals (P ≤ 0.0001). Mice that were treated with 0.7 µM
BAR-NP exhibited levels of bone loss (-0.24 ± 0.05 mm) that approached
uninfected animals. Moreover, 0.7 µM BAR-NP-treated mice showed bone loss
levels that were significantly lower than bone loss observed in 0.7 or 3.4 µM free
BAR-treated mice (P ≤ 0.0001and P ≤ 0.01, respectively) (Figures 3.3).
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Figure 3.2 Representative images from different in vivo treatment groups (n=8 per
group), of the area between the cemento-enamel junction (CEJ) and alveolar bone
crest (ABC), measured to determine bone loss. Images were taken using a
dissecting microscope fitted with a video imaging marker measurement system
(Sony model VIA-170K; Fryer) at a total magnification of 40x.
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Figure 3.3 Alveolar bone loss in each group relative to uninfected, untreated
control mice. BAR-NP-treated mice showed significant reduction of bone loss
relative to high and low concentrations of free BAR-treated mice. Data represent
the mean ± standard deviation (n=8). Statistical differences between groups are
denoted by **, P ≤0.01; ****, P ≤ 0.0001).
Histological analysis
Representative histopathological images of gingival tissues of all mice are
shown in Figure 3.4. Untreated uninfected gingival tissue shows normal structure
without inflammatory cell infiltration. However, heavy infiltration of inflammatory
cells and engorgement of blood vessel are observed in gingival tissue of Pg/Sg
infected mice as a sign of chronic inflammation, as depicted with black arrows
(Figure 3.4B). While, gingival tissues of free BAR and BAR-NP-treated mice
exhibit normal structure with minimal infiltration of inflammatory cells (Figure 3.4C61

E), suggesting that free BAR and BAR-NPs inhibit biofilm formation and
consequently periodontitis. Mice treated with 0.7 µM BAR demonstrated higher
levels of inflammatory cell infiltration relative to control mice; however, still lower
than that observed in Pg/Sg infected mice.

Figure 3.4 Histological sections of murine periodontal tissues, with inflammatory
cell infiltration denoted with black arrows. (A) Periodontal tissue of uninfected,
untreated (control) mice shows normal histological structure without inflammatory
cell infiltration. (B) Periodontal tissue of Pg/Sg infected mice demonstrates
prominent chronic inflammation through proliferation of connective tissue and
heavy infiltration of inflammatory cells. (C) Periodontal tissue of mice treated with
0.7 µM BAR exhibits medium infiltration of inflammatory cells. (D) & (E) Periodontal
tissues treated with a higher concentration of free BAR (3.4 µM) or BAR-NPs show
normal histological structure with minimal infiltration of inflammatory cells. (H&E,
100x).
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IL-17 in Periodontal Tissues
To determine whether free BAR and BAR-NPs reduced gingival
inflammation, IL-17 levels in gingival tissues were evaluated across all treatment
groups (see Figures 3.5A and 3.5B). The gingival tissue of Pg/Sg infected mice
and mice treated with 0.7 µM free BAR demonstrated a statistically significant
increase in IL-17 gingival tissue fluorescence (~2-fold, P ≤ 0.0001 and ~1.5-fold,
P ≤ 0.01) relative to uninfected mice. In contrast, animals treated with 3.4 µM free
BAR or with BAR-NPs exhibited only a slight increase in IL-17 fluorescence (~1.13fold), whereas mice treated with 0.7 µM free BAR showed a ~1.5-fold increase in
IL-17 fluorescence significantly higher than BAR-NP treated mice (P ≤ 0.05).
These results are consistent with the histological analysis of gingival tissues.
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Figure 3.5 (A) Immunofluorescence staining of IL-17 on gingival tissue
demonstrated strong staining of the Pg and Sg infected group compared to the
uninfected, untreated; 0.7 µM BAR; 3.4 µM BAR; and BAR-NP-treated groups. (B)
Quantification of IL-17 levels show that free BAR and BAR-NP-treated groups had
similar IL-17 expression relative to the untreated, uninfected mice; however, mice
treated with a lower concentration (0.7 µM) of free BAR showed slightly higher,
statistically significant IL-17 levels relative to untreated, uninfected and BAR-NPtreated mice. Data represent the mean ± standard deviation (n=5); (*, P ≤ 0.05, ***,
P ≤ 0.001 ****, P ≤ 0.0001).
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Determination of BAR and BAR-NP In Vitro Cytotoxicity
Hemolytic Assay: The cytotoxicity of free BAR and BAR-NPs was initially
evaluated by measuring the hemolytic activity against 1% sheep red blood cells
(RBCs). As shown in Figure 3.6A, RBCs that were incubated with free BAR or
BAR-NPs (1.3 or 3.4 µM), or with PBS (control) showed no hemolysis, suggesting
that free BAR or BAR-NPs have negligible hemolytic activity in erythrocytes.
MTT Assay: To assess the effect of free BAR or BAR-NPs on the viability
of TIGK cells, cultures were incubated with 1.3 or 3.4 µM free BAR for 2 d and
viability was measured using MTT. As shown in Figure 3.6B, treated cells
exhibited little loss in viability, suggesting that free BAR and BAR-NPs are
biocompatible with TIGK cells when applied for up to 2 d.
ATP Assay: Cytotoxicity was also determined by assessing the metabolic
activity of TIGK cells by measuring ATP levels. As shown in Figure 3.6C,
staurosporine-treated cells demonstrated significantly lower levels of ATP (P ≤
0.0001) than were observed for uninfected, untreated; free BAR; and BAR-NPtreated cells. Although the levels of ATP in free BAR and BAR-NP-treated cells
were statistically different from control cells, their levels were still elevated relative
to staurosporine-treated cells.
LDH Assay: Since some peptides are known to damage the cell membrane,
we next measured LDH activity as a marker for cell membrane integrity after
treatment with free BAR or BAR-NPs. Figure 3.6D shows that LDH levels released
from cells treated with free BAR or BAR-NPs (1.3 or 3.4 µM) was negligible when
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compared to control (medium treated) cells. In contrast, LDH activity released from
cells treated with staurosporine was significantly (P ≤ 0.0001) higher than control
or treated cells, suggesting that free BAR and BAR-NPs do not compromise cell
membrane integrity. Finally, we examined the ability of free BAR or BAR-NPs to
induce apoptosis in TIGK cells. Flow cytometry results showed the presence of
minimal apoptotic populations (lower right quadrant) when cells were incubated
with 1.3 and 3.4 µM free BAR (3.5 and 14.9%, respectively) or BAR-NPs (12.2 and
14.2%). In contrast, 89% of cells were apoptotic after treatment with 2 mM
hydrogen peroxide (Figure 3.7, Table 3.2). These results indicate that free BAR
and BAR-NPs do not induce prominent apoptosis of TIGK cells.
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Figure 3.6 (A) The hemolytic activity of free BAR or BAR-NPs (1.3, 3.4 µM) was
assessed after administration to sheep erythrocytes for 3 hr. Hemoglobin release
from free BAR and BAR-NP-treated cells was negligible relative to release from
H2O-treated cells (****, P ≤ 0.0001). (B) TIGK cell viability was assessed after free
BAR or BAR-NPs administration for 2 days. Free BAR and BAR-NPs were nontoxic, relative to cells treated with DMSO (****, P ≤ 0.0001). (C) ATP levels from
free BAR (3.4 µM) and BAR-NP-treated (1.3, 3.4 µM) cells showed decreases in
ATP concentration, relative to control cells (treated with medium only), while ATP
levels in the staurosporine-treated cells were significantly lower than the control
(treated with medium only), free BAR, and BAR-NP-treated cells (****, P ≤ 0.0001).
(D) No significant release of LDH was observed from TIGK cells treated with free
BAR and BAR-NPs, relative to control cells. Staurosporine-treated cells
demonstrated significantly elevated LDH levels (****, P ≤ 0.0001). Data represent
the mean ± standard deviation (n=5).
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Figure 3.7 TIGK cells were treated with (A) medium alone, (B) 1.3 µM free BAR,
(C) 3.4 µM free BAR, (D) 1.3 µM BAR-NPs, (E) 3.4 µM BAR-NPs and (F) 2 mM
hydrogen peroxide. The FITC versus phycoerythrin (PE) fluorescence dot plots
show the live (bottom left quadrant) and apoptotic cell (bottom right quadrant) cell
populations. Data represent the mean ± standard deviation (n=3), 10,000 counts.
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Table 3. 2 TIGK cells apoptosis induced by 1.3 µM free BAR, 3.4 µM free BAR,
1.3 µM BAR-NPs, 3.4 µM BAR-NPs and 2 mM hydrogen peroxide relative to cells
treated with medium alone, (*, P ≤ 0.05, **, P ≤ 0.01 and ***, P ≤ 0.001).
Treatment

% Live Cell

% Early
Apoptosis

% Late Apoptosis

Medium

99.00 ± 1.22

0.80 ± 0.56

0.097 ± 0.06

BAR 1.3 µM

95.60 ± 1.01

3.39 ± 0.17

0.18 ± 0.09

BAR 3.4 µM

84.07 ± 0.81*

15.33 ± 0.51*

0.41 ± 0.24

BAR-NPs 1.3
µM

86.57 ± 2.23*

12.53 ± 1.92*

0.22 ± 0.12

BAR-NPs 3.4
µM

83.90 ± 2.55*

14.77 ± 1.53*

0.60 ± 0.44

2 mM H2O2

12.73 ± 1.59***

87.03 ± 1.70**

0.23 ± 0.17

Discussion
Porphyromonas gingivalis adherence to oral streptococci is a key event in
the initiation and pathogenesis of periodontal diseases, representing a specific
target for therapeutic intervention105. Previous work in our groups has
demonstrated that BAR peptide inhibits biofilm formation by preventing Pg
adherence to streptococci in vitro and in a murine model of infection109,110.
However, the administration of free BAR was significantly less effective in
disrupting existing Pg/streptococcal biofilms111-113. A recent study by our groups
demonstrated the ability of BAR-NPs to deliver a high concentration of peptide to
potently and multivalently inhibit in vitro biofilm formation95. Given this, the aim of
this work was to translate our previous in vitro BAR-NP results to a murine model
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of periodontitis, highlighting the potential of novel specifically-targeted NPs in a
prophylactic oral biofilm application.
Morphological characterization of BAR-modified PLGA NPs showed
spherical NPs with an average diameter of 87.9 ± 29.4 nm and zeta potential of 10.3 ± 0.9 mV, while, the diameter and negative surface charge of unmodified NPs
increased to 155.87± 37.6 nm and -22.6 ± 1.2 mV, respectively. The decrease in
BAR-NP size may be attributed to the increased surface charge imparted by avidin
conjugation, which typically reduces aggregation, consequently decreasing NP
size122,151. The similar, but large increase in size of hydrated NPs, relative to
unhydrated NPs, may be attributed to PLGA swelling in an aqueous solution115,122.
These results are in agreement with typically observed NP values95,122. BAR-NPs
were fabricated using 18 nmol BAR per mg PLGA NP to provide maximum
conjugation of BAR peptide (7.1 nmol/mg NPs) to the NP surface and the
functional stability of BAR-NPs relative to free BAR, was tested through in vitro
biofilm inhibition assays prior to these in vivo experiments.
To expand upon our in vitro studies, we assessed the efficacy of BAR-NPs,
relative to free BAR, to prevent alveolar bone loss in a mouse model of
periodontitis. Mice infected with Pg and Sg showed significantly increased bone
loss relative to that observed in untreated, uninfected mice, or animals infected
with Sg or Pg alone. Treatment with either free BAR or BAR-NPs significantly
reduced bone loss in Pg/Sg infected mice. Treatment with 0.7 µM or 3.4 µM free
BAR reduced bone loss in a dose-dependent manner, but interestingly, treatment
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with 0.7 µM BAR-NPs reduced bone loss to a significantly greater extent than
either dose of free BAR. This is consistent with our previous in vitro observations
that BAR-NPs promote multivalent interactions with Pg95. The reduction of bone
loss arose from reduced Pg-induced gingival inflammation that most likely
occurred through BAR-NP-mediated inhibition of Pg colonization of the oral cavity.
In corroboration with efficacy data, histopathological examination of gingival
tissues showed minor levels of inflammatory cell infiltration in the gingiva of
uninfected animals but significantly increased inflammatory cell infiltration in the
gingiva of Pg/Sg infected mice. Consistent with the bone loss data, treatment with
free BAR or BAR-NPs significantly reduced inflammation. In addition, gingival
tissue levels of the pro-inflammatory cytokine, IL-17, were significantly increased
upon infection and significantly reduced upon treatment. Finally, free BAR and
BAR-NPs exhibited minimal toxicity against TIGK cells using various approaches
to assess cell lysis, induction of apoptosis, or effects of cell viability or metabolism.
Together, these results indicate the utility of BAR-NPs to provide and enhance
protection in a murine model of periodontitis, relative to treatment with free BAR.
To date, a variety of groups have developed polymeric delivery vehicles to
improve traditional treatment and prevention approaches to periodontal
diseases86. However, polymeric delivery vehicles have been primarily developed
to deliver antibiotics85,86,90,152,153 for prolonged durations, and to decrease antibiotic
dose, administration frequency, and associated adverse effects. However,
antibacterial resistance and non-specificity still remain challenges to effectively
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eradicate initial and recurrent biofilms, pathogen resistance, and associated
diseases35,37,107 . While recent studies have demonstrated some success using
various polymeric NPs in dental pathogen murine models 85,86, these studies have
focused on targeting antibiotic NP formulations to epithelial cells with gingival
targeting RGD peptides. Results from these studies indicated that NP surfacemodification improved NP attachment to epithelial cells, maintaining antibacterial
(i.e., minocycline) concentrations in gingival fluid for prolonged durations and
improved therapeutic activity relative to unmodified NPs 94. Other studies have
similarly sought to use RGD94, or more general bioadhesive molecules such as
chitosan124,126 or dimethyl-octyl ammonium134, to obtain improved localization and
adhesion to the dental surface. Strong mucoadhesive properties and adhesion to
the tooth surface were demonstrated for antibacterial NPs modified with these
agents124.
Although non-specific mucoadhesive molecules and broad targeting
molecules such as RGD have demonstrated promise in establishing adhesion, the
challenges surrounding antibiotic active agents have spurred the discovery and
investigation of specifically-targeted molecules against oral biofilms. Antimicrobial
peptide (HHC-36) loaded titanium oxide nanotubes, titanium binding peptide
(TiBP-1), histatin 5, and lactoferricin peptides have been developed to enhance
pre-implant protection against bacterial infection and prevent biofilm formation154156.

In addition, a terminal product of the cyclooxygenase (COX)-2 pathway (15d-

PGJ2) has been administered to inhibit bone resorption in vivo133. PLGA NPs,
encapsulating 15d-PGJ2, localized in gingival tissue, showed potent anti72

inflammatory response by decreasing proinflammatory cytokines, demonstrated
immunomodulatory effects, and decreased bone resorption in a mouse model of
periodontitis after daily s.c. injection133.
In contrast with the non-specific bioadhesive and targeting developments
described above, the goal of this work was to incorporate a pathogen-specific
biological active agent within a surface modification, to exploit the specific and
adhesive interactions between two bacteria known to initiate the process of
periodontal infections. Previous in vitro studies conducted by our group have
demonstrated that BAR-modified NPs exhibit potent biofilm inhibition with a 7-fold
lower IC50, relative to free BAR95, highlighting the benefits of a multivalent delivery
system to enhance binding to target sites. Seminal work in the area of multivalency
demonstrated that multivalent ligands can enhance the strength or binding avidity
to target sites, relative to that observed with monovalent ligands, by increasing the
affinity to target entities while decreasing detachment rates121,145,157. Our prior in
vitro results with BAR-NPs are consistent with the enhanced binding anticipated
via these mechanisms, demonstrating improved effectiveness, with lower BAR
concentration. Importantly, results from our current in vivo studies corroborate the
in vitro multivalent effects, by demonstrating that 0.7 µM BAR, conjugated to a NP
surface, safely and significantly reduces bone loss and inflammation, relative to a
higher concentration of monovalent free BAR (3.4 µM), in a murine model of
infection. Moreover, BAR-NPs, within the range of concentrations examined in this
study, provide a safe method, as assessed with four different studies, to induce
biofilm inhibition. The use of biodegradable FDA-approved polymers, such as
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PLGA, as a core platform, offers the potential for the incorporation of other
complementary active agents, and more seamless integration in pre-clinical and
clinical studies. Ongoing studies in our group will utilize these particles in dual
capacity to both multivalently target specific species of bacteria and to release
active agents simultaneously.
In future studies, we intend to examine different temporal administration
regimens to optimize prevention and treatment approaches with this platform. In
addition, we plan to extend our studies to assess the kinetics of BAR-NPs in the
oral cavity after gingival application, and correlate this with BAR-NP effectiveness
in preventing (or treating) biofilm formation. Moreover, we will evaluate the stability
and longevity of BAR-NP binding with Pg in the oral cavity. Long-term, clinical
studies will focus on formulating BAR-NPs to more conveniently apply BAR-NPs
to the oral cavity, for example, in a mouthwash or gel, with the goal of retaining
BAR-NPs in oral niches for durations spanning 12-24 hr. While existing products
designed for localized periodontal prevention and treatment contain antibiotics,
analgesic, or anesthetic cargos, we envision that this technology may offer a new
way to deliver specifically- acting biologics to the oral cavity.
Conclusions
Building upon our previous in vitro work, the goal of these studies was to
assess the in vivo efficacy and safety of BAR-NPs in a murine model of
periodontitis. We hypothesized that BAR-NPs may more potently and safely inhibit
Pg virulence in vivo by delivering a high localized concentration of BAR, and
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improving BAR effectiveness through multivalent interactions with Pg. The in vivo
efficacy of BAR-NPs was evaluated in a periodontitis murine model by measuring
bone loss, histologic changes, and gingival IL-17 expression as outcomes of Pginduced inflammation. The safety of BAR-NPs was evaluated by measuring cell
viability, apoptosis, ATP and LDH levels in TIGK cells and hemolytic activity in
sheep erythrocytes. BAR-NPs significantly reduced bone loss and IL-17
expression in Pg/Sg infected mice to levels of sham-infected mice, and to a greater
extent than an equimolar amount of free BAR. Moreover, BAR-NPs and free BAR
showed non-hemolytic activity and demonstrated greater than 90% viability, with
apoptosis, ATP and LDH levels similar to untreated cells. Our results suggest that
BAR-NPs provide a potent platform to inhibit Pg virulence, relative to free BAR,
while eliciting a safe, non-toxic effect within the evaluated concentration range of
1.3 - 3.4 µM on gingival and erythrocytic cells, suggesting this novel therapeutic
approach for delivery to the oral cavity.
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CHAPTER 4
RAPID-RELEASE POLYMERIC FIBERS FOR INHIBITION OF
PORPHYROMONAS GINGIVALIS AND STREPTOCOCCUS GORDONII
BIOFILMS
Introduction

Various mechanical prophylactic therapies including scaling and root
planning are only temporarily effective in removing the subgingival biofilm to halt
the inflammatory cascade29, since the biofilm begins to re-form shortly after
prophylaxis is completed. Furthermore, while current medicinal therapies,
consisting of systemic and local administration of antibiotics are initially effective,
they can result in side effects due to an inadequate concentration of drug reaching
the periodontal pockets resulting in transient activity35,37,107, and lead to the
development of antimicrobial resistance. Moreover, the non-specific nature of
current antibiotic agents can adversely impact the commensal microbial
community. Given these challenges, new prophylactic and therapeutic approaches
that provide more specific targeting of periodontal pathogen interactions are
urgently needed to address these shortcomings and to improve oral therapeutic
outcomes.
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Delivery vehicles that localize the delivery and maintain the stability of
specifically-targeted biologics, such as BAR peptide, may offer improved functional
activity, thereby enhancing the therapeutic efficacy28. Delivery platforms such as
electrospun fibers (EFs) have been used in a variety of applications like wound
dressing158, tissue regeneration159,160 and antimicrobial delivery98,97 to incorporate
water-soluble bioactive agents such as proteins, peptides, nucleic acids and
hydrophilic/hydrophobic drugs. Polymeric fibers can protect encapsulated cargo
from systemic absorption and associated side effects. Moreover, electrospinning
offers a cost-effective, reproducible, and highly tunable method to provide efficient
encapsulation and release based on the needs of rapid-onset or prolonged delivery
applications. Many studies have shown that fibers composed of polymer blends
have the potential to tune drug miscibility and that the resulting drug-polymer
interactions may lead to different release profiles99. A number of natural, synthetic
and

semi-synthetic

polymers

have

been

used.

Since

biocompatible,

biodegradable, and Food and Drug Administration (FDA) approved polymers
including poly(lactic-co-glycolic) acid (PLGA)102, poly(L-lactic acid) (PLLA)103,
polycaprolactone (PCL)97, and polyethylene oxide (PEO)104 have been
successfully electrospun into fibers, using this approach, we hypothesized that EFs
may offer advantages to the administration of BAR peptide in the oral cavity.
We previously showed that BAR-modified and BAR-encapsulated
nanoparticles (NPs) inhibit Pg biofilm formation95,96,143. These NPs were
envisioned to serve in formulations such as an oral gel, varnish or mouthwash that
require two to three daily applications. Here we sought to develop and characterize
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EFs that may be administered in future applications, as rapid-release dental strips
in the oral cavity. We hypothesized that BAR release may be modulated by
changing the hydrophobic:hydrophilic polymer ratios of the blended fibers. We
synthesized

blended

EF

formulations

and

showed

that

changing

the

hydrophobic:hydrophilic polymer ratios altered the release kinetics of BAR peptide
and functionally characterized their effectiveness in preventing the formation of
Pg/Sg biofilms in vitro. These results suggest that BAR-incorporated EFs can be
formulated to release peptide over a time window of hours and may represent a
new dosage form that can release targeting molecules in the oral cavity. Longterm, we envision that BAR-EFs may provide a promising rapid-release platform
to deliver BAR peptide to the oral cavity in the form of strips or gum that can be
applied twice daily to inhibit biofilm formation.
Materials and Methods
Materials
Hydrophobic polymers including poly(lactic-co-glycolic acid) (PLGA, 50:50
lactic:glycolic acid, MW 30,000-60,000), poly(L-lactic acid) (PLLA, MW 50,000),
and polycaprolactone (PCL, MW 80,000), and the hydrophilic polymer,
polyethylene oxide (PEO, MW 100,000) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Tris-EDTA (TE) buffer (pH 8.0), phosphate buffered saline (PBS)
and the organic solvents chloroform, dimethyl sulfoxide (DMSO), and
hexafluoroisopropanol (HFIP) were also purchased from Sigma-Aldrich (St. Louis,
MO, USA). All chemicals were used directly without further purification. One
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milliliter plastic syringes, petri dishes, and 20 mL scintillation vials were obtained
from VWR. One milliliter glass syringes were purchased from Fisher Scientific. The
electrospinner was provided courtesy of Dr. Stuart Williams at the Cardiovascular
Innovative Institute, University of Louisville.
Peptide Synthesis
The

peptide

used

in

LEAAPKKVQDLLKKANITVKGAFQLFS-COOH)112

this
was

study
synthesized

(NH2by

BioSynthesis, Inc. (Lewisville, TX). It was obtained with purity greater than 90%
and comprised residues 1167 to 1193 of the SspB (Antigen I/II) protein sequence
of Sg. A fluorescent BAR peptide (F-BAR), synthesized by covalently attaching 6carboxyfluorescein (F-BAR) to the epsilon amine of the lysine residue underlined
in the sequence above, was used to more easily characterize BAR loading and
release from the fibers via fluorescence detection.
Preparation of Polymer Solutions
To prepare the hydrophobic-only polymer fiber batches, PLGA and PLLA
were dissolved in HFIP at a concentration of 15% (w/w), while PCL was dissolved
in HFIP at a concentration of 12% w/w due to increased viscosity. The polymer
solutions were aspirated into a 7 mL glass scintillation vials, and sealed using
parafilm to prevent evaporation of the organic solvent. The vials were placed in a
shaker at 150 rpm and incubated at 37°C overnight to solubilize the polymer. The
final volume of each polymer solution was 1 mL. The following day, F-BAR peptide
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was dissolved in 200 µL TE buffer. The F-BAR solutions were mixed with the
polymer solvents at a concentration of 1% w/w (e.g., 2.4 mg BAR/240 mg polymer).
To prepare blended polymers, the hydrophobic polymers PLGA, PLLA, and PCL
were mixed with PEO at different ratios (40:60, 20:80, 10:90 w/w) to form
PLGA:PEO, PLLA:PEO, and PCL:PEO blends in chloroform at a concentration of
15% (w/v). The blended solutions were aspirated into 20 mL glass scintillation
vials, and sealed using parafilm to prevent evaporation of the organic solvent. The
vials were placed in a shaker at 150 rpm and incubated at 37°C overnight to
solubilize the polymer. The final volume of each polymer solution was 1 mL. The
following day, F-BAR peptide was dissolved in 60 µL DMSO. The F-BAR solutions
were mixed with the polymer solvent at a concentration of 1% w/w (BAR/polymer
content).
Electrospinning
For the non-blended polymer solutions, 1 mL of the mixed polymer
suspension was aspirated into a 1 mL plastic syringe with an 18-gauge blunt
needle tip. The internal diameter of the BD plastic syringe (4.78 mm), was set in
the syringe pump program. The collector was adjusted such that there was at least
10 cm distance maintained from the needle tip. The syringe pump motor controls
were adjusted by setting the “slide” control to 4.5 and the “rotor” to 8. The voltage
supply was set at 20 kV, and the syringe pump flow rate was set to 0.8 mL per
hour. The polymer solution was electrospun at room temperature, under
atmospheric conditions, for 1 hr 15 min, and the resulting fine mist was collected
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on the mandrel and allowed to dry for 15 min (Figure 4.1). The mandrel was
removed from the collector and the fiber was cut and gently peeled off the mandrel.
The fiber was placed in a labeled petri dish and kept in a desiccator for 24 hr before
characterization. The desiccated fibers were stored in 4°C until use.
For the blended polymer solutions, 1 mL of the mixed dual-polymer
suspension was aspirated into a 1 mL glass syringe with a 22-gauge blunt needle
tip. The internal diameter of the Hamilton gastight syringe (4.61 mm), was set in
the syringe pump program. A distance of 15 cm was kept between the needle tip
and the collector. The “slide” control was set to 4.5 and the “rotor” control was set
to 8. A voltage of 20-25 kV was applied, at a flow rate of 0.3 mL per hr. The
electrospinning processes were employed under ambient conditions for 3 hr 20
min. The stretched and solidified polymeric fibers were collected on a 4 mm
diameter stainless steel mandrel and allowed to dry for 15 min. Similar desiccation
and storage conditions were followed, as noted for the non-blended fibers.
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Figure 4.1 Schematic representation of electrospinning process. Adapted from
http://www.people.vcu.edu/~glbowlin/research.html.
EF Characterization: EF Morphology, Diameter, BAR Loading, and Release
Fiber morphology and size were evaluated using scanning electron
microscopy (SEM) (JSM-820, JEOL, Tokyo, Japan), and fiber diameters were
obtained by analyzing SEM images with NIH ImageJ. The loading and
encapsulation efficiency (EE) of F-BAR peptide in the non-blended and blended
fibers were determined by dissolving F-BAR fibers in DMSO. The fiber solution
was subsequently vortexed, sonicated for 5 min, and dissolved for 1 hr in a dark
room. The quantity of extracted F-BAR was determined by measuring the
fluorescence using a spectrophotometer (488/518 nm excitation/emission),
relative to an F-BAR standard. A standard curve of F-BAR was obtained by adding
0.1 mg F-BAR to 1 mL of 1:9 DMSO:TE, and serially diluting in 1:9 DMSO:TE. The
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diluted solutions (100 µL/well) were transferred to a 96-well clear bottom microtiter
plate in triplicate. For the dissolved fiber samples, after the incubation period, the
fiber sample solutions were vortexed and sonicated again. The solutions were
diluted 1:2, 1:5, 1:10 and 1:100 in 1:9 DMSO:TE solution, and transferred to a
microtiter plate.
The in vitro release of F-BAR from fibers was measured by gentle agitation
of EFs in phosphate buffered saline (PBS, pH 7.4) at 37°C. At fixed time points (1,
2, 4, 8, 12, and 24 hr), samples were collected and the amount of F-BAR released
from the EFs was quantified via fluorescence spectroscopy, against an F-BAR
standard in PBS.
Growth of Bacterial Strains
Pg (ATCC 33277) was grown in Trypticase soy broth (Difco Laboratories
Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL
menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently
inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aerobically without shaking in brain-heart infusion broth (Difco Laboratories Inc.)
supplemented with 1% yeast extract for 16 hr at 37°C.
Biofilm Inhibition Assay
To assess the effectiveness of BAR-incorporated EFs to prevent the
interaction of Pg with Sg, Sg was harvested from culture and labeled with 20 µL of
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5 mg/mL hexidium iodide for 15 min at room temperature. Following incubation,
cells were centrifuged to remove unbound fluorescent dye. The bacterial
concentration was subsequently measured by the O.D. (600 nm) from twenty-fold
diluted cultures of Sg. The optical density of Sg cells was adjusted to 0.8 O.D.
(1 × 109 CFU/mL) to obtain uniformity between cell counts in each well. After
adjusting the optical density, 1 mL of Sg cells was added to each well of 12-well
culture plates containing a sterilized micro-coverslip. The cell culture plates were
wrapped in aluminum foil to protect the labeled cells from light and placed on a
rocker platform in the anaerobic chamber for 24 hr.

Pg cultures were optimized

using a similar approach, utilizing a different fluorescent label (20 µL of 4 mg/mL
carboxyfluorescein–succinylester). Pg was incubated with the fluorescent dye for
30 min on a rocker platform and protected from light. The same procedures were
followed as performed with Sg to determine cell concentration, with slight
adaptations. The optical density of Pg was adjusted from 0.8 to 0.4 O.D.
(5 × 107 CFU/mL) by diluting Pg cultures with an equal volume of 1X PBS
containing BAR-EFs, free BAR, or blank EFs as a control, to a final volume 1 mL.
The final concentration of BAR- EFs or free BAR ranged from 0.3-3 µM based on
the previously determined IC50 of free BAR (1.3 µM). Pg was incubated with BAREFs, free BAR, or blank EFs at 25°C for 30 min before transferring to wells
containing Sg.
Plates containing Pg and Sg were subsequently incubated for 24 hr at 37°C
in anaerobic conditions. The following day, the supernatant was removed and cells
were washed with PBS. Adherent cells were fixed with 4% (w/v) paraformaldehyde
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and the cover glass was mounted on a glass slide. Biofilms were visualized using
a Leica SP8 confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL)
under 60x magnification. Background noise was minimized using software
provided with the Leica SP8 and three-dimensional z-stack biofilm images were
obtained from 30 randomly chosen frames using a z-step size of 0.7 μm. Images
were analyzed with Volocity image analysis software (version 6.3; Perkin Elmer,
Waltham, MA, USA) to determine the ratio of green to red fluorescence (GR),
representing Pg and Sg, respectively. Control samples were used to subtract
background levels of auto-fluorescence. Briefly, triplicate samples of Sg alone
were immobilized without Pg or BAR in 12-well culture plates and the same
procedures for dual-species biofilm were followed. Sg-only coverslips were
visualized and images were analyzed as described above. The GR background
was subtracted using the following formula: GR sample or control - GR Sg-only.
Each treatment group (BAR-EFs or free BAR) was analyzed in triplicate and three
independent frames were measured for each well. GraphPad InStat (La Jolla, CA)
was used for data analysis and differences were considered to be statistically
significant when P ≤ 0.05. The percent inhibition of Pg adherence was calculated
with the following formula: GR sample/GR control.
Biofilm Disruption Assay
The same procedures utilized in the inhibition assay were followed, except
Pg was allowed to adhere to streptococci in the absence of BAR peptide or BAREFs to demonstrate the ability of BAR-incorporated EFs to disrupt or “treat” pre85

established biofilms. The resulting Pg/Sg biofilms were then treated for the
maximum duration observed for free BAR to disrupt existing biofilms (3 hr) 95.
Established biofilms were administered BAR-EFs, free BAR or blank EFs at
various concentrations in 1mL PBS, and processed and analyzed as described
above. The mean and standard deviation (SD) between samples were determined
and the percent disruption of Pg adherence was calculated with the following
formula: GR sample/GR control.
Tissue Culture
Telomerase immortalized gingival keratinocytes (TIGKs) were grown on 12well collagen-coated plates (Becton Dickinson, Bedford, MA) and cultured using
DermaLife

K

Calcium

Free

Medium

(LifeFactors®)

supplemented

with

penicillin/streptomycin (100 U/mL final concentration; St. Louis, MO), insulin (5
µg/mL), recombinant human (rh), L-glutamine (6 mM), apo-transferrin (5 µg/mL),
epinephrine (1 µM), rh TGF-α (0.5 ng/ mL), extract PTM, calcium chloride (0.06 mM)
and hydrocortisone hemisuccinate (100 ng/mL). The cells were incubated at 37°C
in the presence of 5% CO2 for 6 days until they reached 95% confluence.
Determination of BAR and BAR-EFs In Vitro Toxicity
Hemolytic Assay: A sample of 250 µL of 1% sheep erythrocytes (Rockland
Inc, Pennsylvania, USA) was suspended in sterile PBS. 1.3 and 3.4 µM (the
maximum concentrations used in in vitro and in vivo studies) of BAR peptide or
10:90 PLGA:PEO BAR-EFs were added to sheep erythrocytes. Water replaced
PBS as a positive control for cell hemolysis. The suspension was incubated at
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37°C for 3 hr then centrifuged at 3,500 x g, Hemoglobin released due to cell lysis
was analyzed by measuring the absorbance at 541 nm.
MTT Assay: TIGK cells were seeded in 12-well plates at a density of 6 x 104
cells in 1 mL media per well and incubated for 24 hr to allow for 60–70% confluency
and sufficient adhesion. Cells were treated with 1.3 or 3.4 µM of BAR or BAR-EFs.
After 24 hr, 100 µL of MTT solution was added to the media of all samples. After 4
hr incubation at 37°C, 550 µL of lysis buffer was added to the media of each well
and plates were incubated for overnight. The absorbance of each well was read at
570 nm, and the sample absorbance was normalized to the absorbance of
medium-only treated cells. Cells were treated with 10% DMSO media (100 µL
DMSO in 900 µL media) as a positive control for cell death.
ATP Assay: The metabolic activity of cells was assessed by measuring total
ATP levels using the CellTiter-Glo reagent (Promega, Madison WI), as described
by the manufacturer. TIGK cells were seeded at a density of 6 x 104 cells in 1 mL
media per well and incubated at 37°C, 5% CO2 for 24 hr in a 12-well flat bottom
plate. Cells were then incubated with BAR or BAR-EFs (1.3 or 3.4 µM) for 24 hr
at 37°C in 5% CO2. Cells were then lysed with 500 µL of 0.1% Triton X-100 for 30
min at 37°C. The lysates were collected and centrifuged at 1,000 x g for 10 min at
4°C, and 50 µL of supernatant was mixed with 50 µL of CellTiter-Glo reagent.
Samples were incubated at ambient temperature for 10 min in a black 96-well plate
in the dark. Total luminescence was measured with a Victor 3 luminometer (Perkin-
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Elmer, Inc). Cells incubated with 1 ng of staurosporine or with medium-only served
as positive and negative controls for cell death, respectively.
LDH Assay: Cell membrane leakage was measured by assessing the
release of lactate dehydrogenase (LDH). Extracellular LDH was quantified using
a CytoTox96® non-radioactive cytotoxicity assay (Promega, Madison WI) as
described by the manufacturer. TIGK cells were plated at density of 6 x 104 cells
in 1 mL media per well in a 12-well flat bottom plate, and incubated at 37°C, 5%
CO2 for 24 hr. BAR or BAR-EFs (1.3 or 3.4 µM) were added to cells in triplicate for
24 hr at 37°C in 5% CO2. Fifty microliters of supernatant from free BAR and BAREFs-treated (1.3 and 3.4 M) cells were added to the LDH substrate and incubated
at room temperature for 30 min. Then the reactions were terminated by adding 50
L of stop solution. LDH activity was determined by measuring the optical density
of the solution at 490 nm. Positive control cells were treated by Staurosporine,
while negative control cells treated with medium only.
Oxidative DNA Damage: Free radicals and other reactive species are
generated from cells under stress and cause oxidative damage to biomolecules.
DNA is the most targeted site of oxidative attack. Apurinic/apyrimidine (AP or
abasic) site is a prevalent oxidative DNA damage lesion. OxiSelect™ Oxidative
DNA Damage Quantitation Kit (Cell Biolabs, INC., San Diego, CA, USA) was used
to quantify AP sites in cells treated with free BAR or BAR-EFs (1.3 or 3.4 µM) as
described by the manufacturer. TIGK cells were plated at density of 6 x 104 cells
in 1 mL media per well in a 12-well flat bottom plate, and incubated at 37°C, 5%
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CO2 for 24 hr. BAR or BAR- EFs (1.3 or 3.4 µM) were added to cells in triplicate
for 24 hr at 37°C in 5% CO2. Cells treated with medium-only and 2mM H2O2 served
as negative and positive controls, respectively. Genomic DNA was isolated from
TIGK cells by QIAamp DNA Mini kit (Qiagen). AP sites were determined in genomic
DNA by using biotinylated aldehyde reactive probe (ARP) that reacts specifically
with an aldehyde group of AP sites, then were colorimetric detected by a
streptavidin–enzyme conjugate at 450 nm. The quantity of AP sites in DNA
samples was determined by comparing the absorbance with standard curve of
known amount of AP sites.
Statistical Analysis
Data from each of toxicity tests were analyzed using ANOVA after passing
Bartlett's and Brown-Forsythe tests for homogeneity of variances using GraphPad
InStat (La Jolla, CA). A pair-wise, parametric analysis of variance using a
Bonferroni multiple comparison post hoc test was used to determine the statistical
difference among the individual groups. A P-value of ≤ 0.05 was considered to be
statistically significant.
Results
EF Characterization: EF Morphology, Diameter, BAR Loading, and Release
Fibers morphologies and diameters are shown in Figures 4.2 and 4.3. The
average diameters of EFs ranged from 0.7 to 1.3 μm with no statistically significant
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differences observed within or across different formulations, as a function of
polymer type or blend ratio.

Figure 4.2 (A) SEM images of 1% w/w BAR PLGA, PLLA, and PCL non-blended
fibers. (B) SEM images of 40:60, 20:80, and 10:90 1% w/w BAR blended
PLGA:PEO, PLLA:PEO and PCL:PEO fibers.
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Figure 4.3 Average diameters of electrospun ﬁbers measured from SEM images,
using ImageJ. (A) Non-blended and blended (B) 40:60, (C) 20:80, and (D) 10:90
PLGA:PEO, PLLA:PEO and PCL:PEO 1% w/w BAR fibers. Error bars represent
the mean ± the standard deviation (n=3) of three independent runs.
BAR Loading and Release
The overall polymer yield after electrospinning ranged from 40-60% for the
non-blended fiber formulations, while the blended fibers achieved higher yields
spanning 80-90%. The total F-BAR loading for non-blended and blended EFs
ranged between 4.6 – 6.9 µg BAR/mg polymer and 6.0 – 9.2 µg BAR/mg polymer,
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respectively, indicating that high loading of F-BAR was achieved in all fiber
formulations (Table 4.1). To determine the amount of F-BAR release from the
different fiber formulations, F-BAR EFs were incubated in PBS at 37°C. The
fluorescence of the collected supernatant was measured at 1, 2, 4, 8, 12 and 24
hr. Figure 4.4 shows the cumulative release of F-BAR from non-blended EFs at
each time point over a 24 hr duration. PLGA EFs demonstrated minimal release of
F-BAR (9.5% of total loading) after 24 hr, while PLLA and PCL fibers showed even
less release during the same duration. Overall, EFs consisting of only hydrophobic
polymers (i.e., non-blended formulations) demonstrated minimal release relative
to the PEO-blended EFs.
Figure 4.5 shows the release of F-BAR from blended PLGA:PEO,
PLLA:PEO and PCL:PEO fibers with different blend ratios (40:60, 80:20, 90:10),
as a function of hydrophobic polymer type. The importance of the PEO ratio in
each hydrophobic fiber type, is shown in Figure 4.5, with the 10:90 formulation
providing maximum release of F-BAR for each hydrophobic blend. Fibers
comprised of 10:90 PLGA:PEO released 8.25 µg/mg, corresponding to 93% of the
incorporated F-BAR within the first 2 hr, relative to PLLA:PEO and PCL:PEO 10:90
fibers with 65% and 45% of F-BAR release, respectively (Figure 4.6). A significant
reduction in the release of F-BAR was observed after 2 hr for all 10:90
formulations. For the 20:80 blended formulations, the PLGA:PEO fibers showed
maximum release of 88%, compared to PLLA:PEO and PCL:PEO at 58% and
25%, respectively, after 2 hr. Similar trends in F-BAR release were observed for
the 40:60 formulations with PLGA:PEO exhibiting the maximum release of 78%,
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and PLLA:PEO and PCL:PEO releasing 45% and 17% after 2 hr. Of the tested
formulations 40:60 PLGA:PEO, PLLA:PEO and PCL:PEO released the least FBAR within the first 2 hr, and a significant reduction in release was observed after
~4 hr for both the 20:80 and 40:60 formulations. Overall, the release trends for the
different ratios of polymer blends were similar, with PLGA blends achieving the
highest F-BAR release, followed by PLLA and PCL formulations.
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Table 4.1 The amount of BAR loaded in non-blended and blended polymeric EF
formulations (µg/mg) and percent of total BAR loaded in blended and blended EFs.
High loading capacity and encapsulation efficiency was achieved with all fiber
formulations. However, non-blended EFs showed comparatively lower polymer
yield and encapsulation efficiency, relative to the blended EFs. Data represent the
mean ± standard deviation (n=3) of three independent samples.

Overall Polymer

Loading

Encapsulation

Yield

BAR/Fiber

Efficiency

(%)

(µg/mg)

(%)

59.0

6.9 ± 0.1

69 ± 2.5

51.0

6.0 ± 0.4

60 ± 4.0

PLLA

42.3

4.6 ± 0.6

46 ± 5.2

PLGA:PEO

82.9

7.4 ± 0.5

74 ± 5.5

91.5

8.6 ± 0.2

86 ± 2.4

PLLA:PEO

82.0

9.1 ± 0.3

92 ± 3.1

PLGA:PEO

80.9

8.8 ± 0.2

88 ± 2.6

89.3

8.9 ± 0.4

89 ± 4.0

PLLA:PEO

85.2

8.3 ± 0.4

83 ± 4.2

PLGA:PEO

82.8

8.8 ± 0.5

88 ± 5.6

80.0

6.0 ± 0.4

60 ± 4.0

80.9

8.5 ± 0.3

85 ± 3.5

Fiber
Formulation

Blend
Ratio

PLGA
PCL

PCL:PEO

PCL:PEO

PCL:PEO
PLLA:PEO

100:0

40:60

20:80

10:90

94

Figure 4.4 The cumulative release of F-BAR from 1% w/w F-BAR non-blended
(100:0) PLGA, PLLA and PCL fibers. The cumulative release is reported as (A) µg
F-BAR per mg of fiber, and (B) percent of total loaded F-BAR. PLGA showed the
greatest release of incorporated BAR among the non-blended formulations at 24
hr. Error bars represent the mean ± the standard deviation (n=3) of three
independent runs.
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Figure 4.5 The cumulative release of F-BAR from 1% w/w F-BAR blended
PLGA:PEO, PLLA:PEO and PCL:PEO fibers (A) 40:60, (B) 20:80, and (C) 10:90.
The cumulative release is reported as the total quantity of F-BAR released on the
left (µg F-BAR per mg of fiber), and as the percent of total loaded F-BAR on the
right. Error bars represent the mean ± the standard deviation (n=3) of three
independent runs.
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Figure 4.6 The cumulative release of F-BAR from the non-blended and PEOblended formulations as a function of hydrophobic polymer type (A) PLGA, (B)
PLLA, or (C) PCL and PEO ratio in each blend. The release of encapsulated BAR
increases with an increase in PEO fraction. PLGA and PEO blends exhibit the most
significant and rapid F-BAR release, relative to PLLA and PCL blends. For all
polymer types, the 10:90 blends show the greatest release of BAR as compared
to the 20:80 and 40:60 formulations at any given time point. PLGA:PEO (10:90)
fibers provide the highest amount of BAR release across formulations. Data
represent the mean ± standard deviation (n=3) of three independent runs.
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Pg/Sg Biofilm Inhibition
Given that the PLGA blends achieved the highest release of F-BAR, the
ability of the 10:90 PLGA:PEO BAR-EFs to inhibit or “prevent” Pg biofilm formation
was assessed, relative to the administration of free BAR. To assess inhibition,
10:90 PLGA:PEO BAR-EFs or free BAR were administered to Pg for 24 hr.
Subsequently, BAR-EF or free BAR-treated Pg was incubated with immobilized
Sg. As shown in Figures 4.7 and 4.9A, Pg adherence was significantly reduced
in the presence of 10:90 PLGA:PEO BAR-EFs. Biofilm formation was inhibited by
31, 42, or 82% by 0.3, 0.7, and 3.0 µM BAR-EFs. The maximum inhibition
observed was similar to the 81% inhibition observed with free BAR (3 µM). BARincorporated EFs potently inhibited biofilm formation in a dose-dependent manner
(IC50 = 1.3 µM); however, no statistically significant differences (P > 0.05) in
inhibition between BAR-incorporated EFs and free BAR were observed.
Pg/Sg Biofilm Disruption
The ability of the 10:90 PLGA:PEO BAR-incorporated EFs to disrupt or
“treat” pre-existing Pg/Sg biofilms was assessed (Figures 4.8 and 4.9B). Dualspecies biofilms were formed for 24 hr, and were subsequently incubated for 3 hr
with BAR-incorporated EFs or free BAR. Biofilm formation was disrupted by 29,
34, or 66% by 0.3, 0.7, and 3.0 µM BAR-EFs. The maximum inhibition observed
was similar to the 66% inhibition observed with free BAR (3 µM). Taken together,
BAR-EFs exhibited efficient biofilm disruption (IC50 = 2 µM) that was similar to free
BAR (P > 0.05).
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Figure 4.7 BAR-incorporated PLGA:PEO (10:90) EFs prevent Pg adherence to
Sg. Biofilms were visualized with confocal microscopy and the ratio of green (Pg)
to red (Sg) fluorescence in z-stack images was determined using Volocity image
analysis software. Each grid represents 21 µm.
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Figure 4.8 BAR-incorporated PLGA:PEO (10:90) EFs disrupt pre-established PgSg biofilms. Biofilms were visualized with confocal microscopy and the ratio of
green (Pg) to red (Sg) fluorescence in z-stack images was determined using
Volocity image analysis software. Each grid represents 21 µm.
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Figure 4.9 (A) Biofilm inhibition and (B) biofilm disruption, as a function of different
concentrations of BAR-incorporated PLGA:PEO (10:90) EFs and free BAR (3 µM).
Data represent the mean ± standard deviation (n=6).
Assessment of BAR and BAR-EFs In Vitro Cytotoxicity
Hemolytic Assay: The cytotoxicity of free BAR and 10:90 PLGA:PEO BAREFs was initially assessed by measuring the hemolytic activity against sheep red
blood cells (RBCs). As shown in Figure 4.10A, neither free BAR nor BAR-EFs (1.3
or 3.4 µM) induced hemolysis of RBCs.
MTT Assay: To determine the effect of free BAR or BAR-EFs on TIGK cell
viability, cells were treated with free BAR or BAR-EFs (1.3 or 3.4 µM) and viability
was assessed using the MTT assay. As shown in Figure 4.10B, free BAR (1.3 or
3.4 µM) treated cells exhibited little non-significant loss in viability while BAR-EF
(1.3 or 3.4 µM) treated cells showed higher viability, relative to medium-only
treated cells.
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ATP Assay: The metabolic activity of TIGK cells was assessed by
measuring ATP levels. As shown in Figure 4.10C, cells treated with free BAR (1.3
or 3.4 µM) and BAR-EFs (1.3 µM) showed negligible decreases in ATP relative to
medium-only treated cells, while, cells treated with BAR-EFs (3.4 µM) exhibited
slightly lower levels of ATP relative to medium-only treated cells (P ≤ 0.01).
Staurosporine-treated cells demonstrated significantly lower levels of ATP (P ≤
0.0001) than were observed for medium-only, free BAR, and BAR-EF treated cells.
LDH Assay: Since some peptides are known to damage the cell membrane,
LDH released in the cell media was evaluated as a marker for cell membrane
integrity after free BAR or BAR-EF treatment. Figure 4.10D shows that free BAR
or BAR-EFs (1.3 or 3.4 µM) induced a little non-significant increase in release of
LDH from cells, relative to LDH levels released from medium-only treated cells.
However, staurosporine induced a significantly higher level of LDH released from
TIGK cells relative to LDH released from cells treated with medium-only, free BAR,
and BAR-EFs (P ≤ 0.0001).
Oxidative DNA Damage: AP sites were determined as oxidative stress
marker for cells treated with free BAR or BAR-EFs (1.3 or 3.4 µM). As shown in
Figure 4.11, free BAR or BAR-EF treated (1.3 or 3.4 µM) cells demonstrated
negligible changes in AP sites relative to medium-only treated cells. While cells
treated with 2 mM H2O2 exhibited a significant increase of AP sites relative to free
BAR, BAR-EFs (1.3 or 3.4 µM) and medium-only treated cells (***, P ≤ 0.001).
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Results suggested that neither free BAR nor BAR-EFs (1.3 or 3.4 µM) induced
oxidative stress in TIGK cells.
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Figure 4.10 (A) The hemolytic activity of free BAR or 10:90 PLGA:PEO BAR-EFs
(1.3, 3.4 µM) was assessed after administration to sheep erythrocytes for 3 hr.
Free BAR and BAR-EFs showed negligible hemolysis for sheep erythrocyte
relative to release from H2O-treated cells (****, P ≤ 0.0001). (B) Free BAR and
BAR-EFs were non-toxic, relative to cells treated with DMSO (****, P ≤ 0.0001).
(C) BAR-EFs (3.4 µM) treated cells showed decreases in ATP levels relative to
medium-only treated cells, while TIGK cells treated with staurosporine
demonstrated lower ATP levels than the cells treated with medium-only, free BAR,
and BAR-EFs (****, P ≤ 0.0001). (D) None of free BAR or BAR-EF (1.3, 3.4 µM)
treated cells released a significant level of LDH relative to medium-only treated
cells. Staurosporine-treated cells demonstrated significantly elevated LDH levels
(****, P ≤ 0.0001). Data represent the mean ± standard deviation (n=5) of five
independent experiments.
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Figure 4.11 Amount of AP sites per 100000 bp of genomic DNA obtained from
TIGK cells treated with free BAR or BAR-EFs (1.3, 3.4 µM). Level of AP sites of
cells treated with free BAR or BAR-EFs (1.3, 3.4 µM) demonstrated negligible
changes relative to medium only treated cells. However, TIGK cells treated with 2
mM H2O2 demonstrated significantly (***, P ≤ 0.001) higher level of AP sites
relative to control, free BAR and BAR-EFs (1.3, 3.4 µM). Data represent the mean
± standard deviation (n=3) of three independent runs.
Discussion
Periodontal disease is one of the most widespread oral diseases among the
adult population worldwide, resulting in degradation of the supporting tissues of
the teeth, and contributing to dental and systemic diseases 41,161. Porphyromonas
gingivalis, both a prominent component of the oral microbiome and a successful
colonizer of the oral epithelium162, has been suggested to function as a keystone
pathogen, as it facilitates a change in both the amount and composition of the
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normal oral microbiota and creates dysbiosis between the host and dental
plaque42. The initial species-specific supragingival interaction between Pg and Sg
is considered to initiate the biofilm formation process 163 and is mediated by
interaction of the Mfa1 protein of Pg and the SspB polypeptide of Sg164. Since this
interaction is an initial event that promotes Pg colonization of the oral cavity, it
represents an ideal point for therapeutic intervention.
A discrete motif of the SspB polypeptide designated, SspB Adhering Region
(BAR), was identified164, and a synthetic peptide encompassing this motif potently
limited Pg colonization both in vitro and in vivo. Despite this, BAR was shown to
be less effective against well-established and complex biofilms, requiring
prolonged exposure to be effective. The objective of this work was to synthesize
and characterize EFs as a new dosage form to deliver the bioactive molecule,
BAR, against biofilm formation for durations relevant to oral administration. We
hypothesized that BAR-incorporated EFs, would provide a new platform to enable
the short-term release of therapeutically relevant concentrations of BAR to be
applied twice daily. Moreover, we hypothesized that BAR release from EFs may
be modulated by changing the hydrophobic polymer type and PEO blend ratios.
Local drug delivery vehicles in the form of films165, strips166,167, and wafers168
have been applied to periodontal disease, where the subgingival pockets act as a
natural reservoir for these drug-loaded carriers. However, the methods used to
fabricate these dosage forms include solvent casting, melt spinning and direct
milling methods, which often prove to be labor intensive, time consuming, and
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expensive. In contrast, electrospinning may provide a simple-to-use, time and costefficient process.

In addition, EFs offer several advantages relative to other

dosage forms including the large surface-to-volume ratio, which can provide
increased contact between the encapsulated bioactive molecule and the
surrounding medium and tissue environment; small diameter fibers for efficient
drug release; the ability to tailor different drug release profiles; and mechanical
stability169. Here we envisioned that designing EFs targeted to the oral cavity may
provide a new dosage form in which to administer BAR, relative to the
administration of free BAR, and may provide a mechanism to improve therapeutic
outcomes by increasing the localized concentration of BAR. Long-term, we
envision BAR-EFs may be administered as dental strips or in gel form to degrade
and avoid surgical removal after application.
To date, polymeric EFs have been used as delivery vehicles in several
biomedical

applications

including

wound

dressing

materials158,

tissue

regeneration159,160, and as drug delivery vehicles for bioactive molecules,
antimicrobial agents97, anti-inflammatory drugs170, and anesthetics171. Moreover
PLGA fibers have provided cell scaffolds160, and have been combined with other
polymers including PCL and PLA to deliver traditional antibiotics such as
doxycycline97 and metronidazole for the localized treatment of periodontitis98,172.
However, hydrophobic-only fibers have exhibited delivery limitations such as poor
wettability, combined with inadequate flexibility and stiffness properties. Despite
this, these and other more biodegradable fiber types such as polydioxanone and
PLA:PCL/Gelatin fibers incorporating ciproflaxin and tetracycline respectively,
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have significantly inhibited periodontal pathogens without affecting the growth of
beneficial commensal oral bacteria173,174.
Given this favorable potential, our goal was to fabricate and compare nonblended (hydrophobic-only polymer fibers) with blended BAR-incorporated EFs
using a uniaxial electrospinning approach. We initially formulated 1% w/w fibers
(BAR/polymer), resulting in a theoretical loading of 10 g BAR per mg of polymer,
a concentration shown in our previous work to inhibit biofilm formation. All resulting
EFs demonstrated high F-BAR loading and encapsulation efficiency, ranging from
4.7 to 9.4 µg/mg and 47-90%, respectively. However, the release kinetics of the
non-blended PLGA, PLLA, and PCL fibers revealed minimal release of the total
incorporated F-BAR over 24 hr. We attributed the high hydrophobicity of the nonblended PLGA, PLLA, and PCL fibers to minimal eluate penetration past the
outermost fiber layer. Moreover, hydrophobic sequences in the BAR peptide may
promote hydrophobic F-BAR interactions with the purely hydrophobic non-blended
fibers, resulting in lower release.
While hydrophobic polymers have been used in numerous applications
outside of the oral cavity, to obtain time frames of release relevant to oral delivery
(once or twice daily), we sought to modulate fiber hydrophobicity with the addition
of hydrophilic PEO in ratios (PLGA/PLA/PCL:PEO 40:60, 20:80 and 10:90).
Previous work has shown that blending hydrophobic polymers with more
hydrophilic polymers increases the release of biological molecules such as
lysozyme, while maintaining protein activity175. In addition, many studies have
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shown that the addition of PEO to protein solutions can improve protein stability175177.

Moreover, recent studies demonstrated that incorporation of PEO with

hydrophobic fibers increased the pore formation and fiber weight loss with rapid
degradation rate relative to non-blended fibers178,179.
By increasing the fiber hydrophilicity with the addition of PEO (PLGA:PEO
40:60, 20:80 and 10:90), BAR release was significantly improved in the blended
fibers. This is in agreement with studies that have shown that by introducing
hydrophilic PEO into fiber formulations, the physical and mechanical properties of
the fiber change, while providing the ability to tune encapsulant (e.g., BAR)
release178. While hydrophobic polymers provide structural integrity to the scaffold,
the PEO makes it more porous, enabling the release of the hydrophilic BAR
peptide. Moreover, by incorporating PEO in EFs our initial goal was to formulate
EFs that would rapidly degrade and release BAR, to avoid removal of EFs after
administration. In addition, hydrophilic molecules have been shown to have more
affinity and compatibility with PEO, explaining the initial burst release presented by
the blended fibers. Last, we postulate that in addition to materials properties, the
electrospinning

process

itself

can

affect

encapsulant

location

within

hydrophobic:hydrophilic blended fibers, prompting variable release kinetics.
During electrospinning, the electric field may promote F-BAR aggregation close to
the fiber surface, due to charge repulsion180. This localization, potentially resulting
in the release of F-BAR only near the fiber surface, may contribute to the burst
release observed in all blended fiber formulations.
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Among

the

hydrophobic

polymers

utilized,

PLGA

formulations

demonstrated the highest release at early time points, followed by PLLA and PCL
formulations. We propose that PLGA fibers demonstrate the highest release due
to its amorphous and less hydrophobic properties, relative to the more hydrophobic
PLLA and PCL polymers. Relative to PLGA:PEO and PLLA:PEO blends, we
propose that PCL:PEO fibers demonstrated the least release due to its crystalline
and slightly more hydrophobic features.
The PLGA:PEO (10:90) fibers exhibited 88% encapsulation efficiency and
90% release of F-BAR, the highest among all the blended and non-blended
formulations within the first 2 hr, with PLLA:PEO (10:90) exhibiting 65% release,
and PCL:PEO (10:90) releasing 45% in the same time frame. Negligible quantities
of F-BAR were released after 24 hr. Taking both encapsulation efficiency and
release properties into consideration, PLGA:PEO (10:90) was selected to evaluate
biofilm efficacy. BAR-incorporated PGLA:PEO 90:10 EFs were evaluated to inhibit
two-species biofilm formation and disrupt pre-existing biofilms, against an
equimolar concentration of free BAR. BAR-EFs potently inhibited biofilm formation
(IC50 = 1.3 µM) in a dose-dependent manner (Figure 4.7). In addition, BAR-EFs
efficiently disrupted pre-existing dual-species biofilms (IC50 = 2 µM) (Figures 4.8
and 4.9B).
The fibers fabricated in this study were formulated with 1% w/w
BAR:polymer. As such, they demonstrated high encapsulation efficiency spanning
60-90%, with burst release in the first 2 hr and minimal release thereafter. To
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achieve the IC50 of BAR (4 µg/mL) at every time point over the duration of 24 hr,
loading capacity must be increased. However, previous work has shown that using
a theoretical loading higher than 1 % w/w100 via uniaxial blended spinning process
may still result in significant initial burst release. To overcome burst release,
optimize the release kinetics, and maintain peptide stability, techniques like coaxial or emulsion electrospinning may be adopted in future work 181,182. Several
studies have used co-axial electrospinning to sustain the release of bioactive
molecules. Moreover, the bioactivity of biological agents may also be maintained
since it is not incorporated into the polymer/solvent solution prior to
electrospinning183.

Alternatively,

emulsion

electrospinning

may

help

to

encapsulate the aqueous agents within the core, to provide sustained and
incremental release of the encapsulant182. These advancements may be helpful in
formulating prolonged-release fiber therapeutics for periodontitis as an intrapocket delivery system, where the fibers can be immobilized in the subgingival
pocket for a longer duration of time.
Targeted drug delivery is required to achieve effective therapy against
periodontal diseases.

Thus,

different

drug

delivery

vehicles

like

gels,

nanoparticles, films and fibers have been developed to combat oral diseases 28.
However, antibiotic side effects, desired

release profiles, and non-specific

targeting are still limitations facing antibiotic184, anti-inflammatory185 and
antiseptic186 loaded polymeric gels currently available to prevent and treat chronic
periodontitis. Moreover, even with these formulations, high loading efficiency,
sterility, and high cost are challenges that need to be addressed. In comparison,
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delivery vehicles that enable the specific targeting of periodontal keystone
pathogens may provide a path to develop a novel formulation that exerts potent
prophylactic or therapeutic effect via specific interactions, in addition to providing
adhesive properties and localized release with minimal side effects.
Our results demonstrated the feasibility, versatility and straightforward
approach

of

electrospinning

EFs

that

release

therapeutically-relevant

concentrations of BAR, to specifically target periodontal pathogens. Fibers with
increasing PEO content significantly enhanced F-BAR release within 4 hr, while
the most promising 10:90 PLGA:PEO formulation provided 95% F-BAR release
after 4 hr, inhibited biofilms in a dose-dependent manner (IC50 = 1.3 M), and
efficiently disrupted dual-species biofilms (IC50 = 2 M). Our results suggest that
BAR-incorporated EFs may provide an alternative and specifically-targeted rapidrelease platform to inhibit and disrupt dual-species biofilms, that we envision may
be applied once or twice daily to exert prophylactic effect in the oral cavity without
the need to remove the fibers after application. We acknowledge that in vivo
delivery of BAR-EFs has challenge such as complex biofilm not be reflected the
more ideal environment in vitro study. Thus, future studies will be focused on
developing targeted BAR-EFs to overcome in vivo applications challenges and
optimizing the release kinetics of BAR from blended EFs for more sustained
durations of 12-24 hr, by utilizing altered fabrication procedures like emulsion and
co-axial electrospinning181,182.
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CHAPTER 5
ASSESSMENT OF TARGETED BAR-ENCAPSULATED NPS AGAINST ORAL
BIOFILMS
Introduction
Polymer NPs have been applied to a variety of applications in dentistry and
have demonstrated success in reducing the number of intracellular bacteria
relative to the administration of free antibiotic, and in penetrating alveolar bone
trabeculae, underlying connective tissue, and even the periodontal pocket areas
below the gum, due to the small NP size. Other NPs have targeted gingival cells
in order to deliver higher local concentrations of antibiotic for a prolonged
period85,86,127,152. Polymer NPs have a variety of attributes including the ability to
encapsulate both hydrophilic and hydrophobic cargos and to provide sustainedrelease of these encapsulated active agents. Moreover, surface-modification of
NPs can increase efficaciousness by targeting active agent directly to impacted
sites. Through surface-modification, polymer NPs may also enhance tissue
adherence, resulting in the delivery of higher localized concentrations of drug, due
to their inherent mucoadhesive properties, via hydrogen bonding, polymer
entanglement with mucins and hydrophobic interactions, or through coating with
mucoadhesive compounds like chitosan55,56,61,66,141,142.
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Despite the variety of mucoadesive polymer NPs used to treat oral biofilms,
there is currently a scarcity of drug delivery vehicles that enable specific and
prolonged delivery of specifically-targeted biologic active agents to the oral cavity.
Previous work from our groups has demonstrated that BAR-encapsulated
NPs may improve efficacy and longevity in the oral cavity, relative to free BAR143.
In addition, BAR-modified NPs delivered a high localized concentration of BAR
peptide and improved BAR effectiveness through multivalent interactions with Pg,
relative to administration of free BAR in in vitro and murine periodontitis
models95,96. While BAR-encapsulated and BAR-modified NPs demonstrated
significant promise to prevent and treat oral biofilms, retention in the oral cavity is
known to be a challenge for mobile NP delivery vehicles. Free NPs may be
removed by salivary flow, resulting in lower retention in the oral cavity,
necessitating higher concentrations of delivery to maintain efficacy.
Previous studies have sought to address this challenge by integrating
carboxymethyl cellulose (CMC)123, poly acrylic acid (Carbopol)187, polyethylene
glycol (PEG)92,188, polyvinyl alcohol (PVA)189 or polyvinyl pyrrolidone (PVP)189,190
into NPs to localize and maintain active agent for longer durations in the oral cavity.
Another study developed chitosan-coated PLGA NPs to promote mucoadhesion
to the buccal surface to localize lovastatin and tetracycline within the oral cavity.
PLGA-lovastatin-chitosan-tetracycline

nanoparticles

demonstrated

higher

localized concentration of tetracycline with sustained-release for a prolonged
period due to the mucoadhesive properties of the NPs and the slow degradation
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rate of chitosan 90. In addition, recently, minocycline-loaded poly(ethylene glycol)poly(lactic acid) (PEG–PLA) NPs were surface-modified with RGD peptides to
target gingival epithelial cells. Targeted minocycline NPs demonstrated potent
anti-periodontitis activity relative to non-targeted NPs and free minocycline in dogs.
Moreover, RGD-modified minocycline NPs delivered a higher localized
concentration of minocycline to the gingiva and retained the effective concentration
for a longer time, relative to minocycline-loaded NPs94.
While a variety of broadly active mucoadhesive molecules have been used
to increase adhesion and retention in the oral cavity, an alternative approach is to
exploit known protein-protein interactions that drive interspecies coaggregations
between oral organisms to promote adhesion to, and target specific niches in the
oral microbiome. For example, recent studies have demonstrated that
coaggregation factor A (CafA) is a cell surface protein of Actinomyces oris that
promotes Actinomyces/Streptococcus coaggregation191. Thus CafA represents an
ideal targeting molecule to promote NP adherence to Sg and specifically deliver
active agent to this niche. We propose that NP modification with CafA will enhance
targeting to streptococcal cells, an initial niche of Pg in the oral cavity54. By
targeting NPs to this niche, we hypothesize that CafA-modified BAR-encapsulated
NPs will deliver higher localized concentrations of BAR and will be retained for a
longer duration, due to specific adhesion to Sg.

115

Materials and Methods
Peptide Synthesis
BAR peptide is comprised of residues 1167 to 1193 of the SspB (Antigen
I/II) protein of Sg with the sequence NH2-LEAAPKKVQDLLKKANITVKGAFQLFSCOOH112. To facilitate conjugation of BAR to the NP surface, the peptide was
synthesized with an N-terminal biotin. Biotinylated BAR was subsequently
attached to NPs that had been modified with palmitylated avidin, as previously
described95. To enable peptide quantification and detection, some preparations of
BAR were modified such that the epsilon amine of the underlined lysine residue of
BAR was covalently reacted with 6-carboxyfluorescein to produce fluorescent BAR
(F-BAR). All preparations of peptides were synthesized by BioSynthesis, Inc.
(Lewisville, TX) and were guaranteed to have greater than 90% purity via RPHPLC analysis.
CafA Synthesis
CafA synthesis was done in the laboratory of Dr. Donald Demuth by Jinlian
Tan. Genomic DNA of Actinomyces oris (ATCC 43146) was isolated from 10 mL
of an overnight culture using the Wizard Genomic DNA purification kit (Promega,
Madison WI) as specified by manufacturer. The cafA gene was amplified by PCR
using 200 ng of genomic DNA as the template and 30 pmol each of the following
primers: Forward: 5’- AAG GAT CCC TGA GGC CGT TCA -3’; Reverse: 5’- CCG
GAA TTC TAC GAC TTG CGG TTG GAG-3’. PCR amplification was conducted
by denaturation at 94°C for 2 min, annealing of primers and template at 63°C for
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30 s, strand extension at 72°C for 2 min 45 s, for 30 cycles followed by a final
extension cycle at 72oC for 5 min.
The PCR product was subsequently electrophoresed in 1% agarose at 90
V for 40 min and the cafA band was excised and purified using the gel purification
kit (Qiagen). The purified cafA DNA (1 g) and a sample of the pGEX-6p-1
expression vector (0.5 g) were digested with BamHI and EcoRI overnight at 37°C.
Prior to ligation, 50 µL of the digested vector were dephosphorylated with 4 µL calf
intestinal alkaline phosphatase (NEB) at 37°C for 30 min. Subsequently, 3 µL of
protease K were added and incubated for 30 min at 50°C to terminate the reaction.
The vector and cafA fragments were purified using the DNA clean and
concentrator kit (Zymoresearch) and ligated with T4 ligase. Ligation reactions
comprised three µL vector, 5 µl cafA fragment, 1 L 10x ligase buffer and 1µL T4
ligase.
The ligation mixture was initially transformed into E. coli Top 10. Fifty µL of
competent E. coli Top 10 were incubated with 5 µL of ligation mixture on ice for 30
min., then the sample was heat shocked at 42°C for 45 s and placed on ice for 2
min. Two hundred µL of SOC media were added, the sample was incubated at
37°C for 1 hr and plated on LB agar. After overnight incubation at 37°C, single
colonies were selected and cultured in 5 ml LB broth supplemented with 100 g
ampicillin. Plasmid purification was carried out using the mini prep kit (Qiagen) and
the cafA insert was excised and confirmed by sequencing.
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For CafA expression, the purified cafA plasmid was transformed into E. coli
BL21 using the transformation protocol described above. After selecting and
confirming the appropriate transformant, 400 mL of LB broth was inoculated with
10 mL of an overnight culture and incubated to OD600nm of 0.5. Protein expression
was induced by the addition of 0.5mM IPTG and the culture was then incubated at
18°C for 17h. After centrifugation at 6000 rpm, the cell pellet was suspended in 40
mL 50mM Tris, 100mM NaCl, 1mg/ml lysozome,10ug/ml Dnase I, protease
inhibitor cocktail, 10mM CHAPS, incubated overnight at 4°C, then for an additional
2 hr at 25°C. The cell suspension was then sonicated for 2 min on ice.
CafA purification was carried out with the Pierce GST Spin Purification Kit
(Thermo Fisher). Seventeen mL of crude cell lysate were bound to the GST column
for 2 hr at room temperature and the column was then centrifuged to remove
unbound protein according to the specifications of the manufacturer. After washing
the column with loading buffer, the GST tag was cleaved by the addition of 50 µL
precision protease (GE Health) and overnight incubation at 4°C. Released CafA
was then collected by centrifugation. The sample was then sequentially dialyzed
against 30 mM, 20 mM, and 10 mM Tris for 2 hr each. CafA purity was determined
by PAGE gels and protein concentration was determined using the BCA assay
(Pierce).
Synthesis of CafA-Palmitate
NPs were conjugated with CafA-palmitate as previously described96,122,146.
Briefly, 8 mg of CafA were dissolved in 1.2 mL of 2% (w/v) sodium deoxycholate
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(NaDC) in PBS and warmed to 37°C. CafA was then reacted with 14-fold molar
excess of the palmitic acid-N-hydroxysuccinimide ester (PA-NHS; Sigma-Aldrich,
St Louis, MO, USA). Palmitic acid-N-hydroxysuccinimide ester was dissolved in
2% (w/v) NaDC at 0.5 mg/mL, and sonicated until well-mixed. Eight hundred
microliters of the PA-NHS solution were added in drops to the reaction vial
containing CafA and allowed to react overnight at 37°C. The reaction solution was
then dialyzed in 1.2 L of 0.15% (w/v) NaDC in PBS at 37°C using a 3,500 molecular
weight cut-off dialysis tube to remove free PA-NHS. After overnight dialysis at
37°C, CafA-palmitate was transferred to a storage vial and stored at 4°C until use.
CafA Surface-Modified Nanoparticle Synthesis
CafA surface-modified NPs were synthesized using a previously described
single-emulsion technique88,121. PLGA with a 50:50 monomer ratio and 0.55–
0.75 dL/g inherent viscosity, was purchased from LACTEL®. Briefly, 100 mg PLGA
was dissolved in 2 mL dichloromethane (DCM) overnight. The following day, 2 mL
of a 5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 mL of 4 mg/mL
CafA-palmitate. The 2 mL PLGA/DCM solution was added dropwise to 4 mL
PVA/CafA-palmitate solution while vortexing. The NP solution was added to 50 mL
of 0.3% PVA for 3 hr to evaporate residual DCM. After evaporation, the NP solution
was centrifuged at 13,000 rpm (20,442 x g) at 4°C. Supernatant was discarded,
and the NPs were washed two times with deionized water (diH2O) by
centrifugation at 13,000 rpm (20,442 x g) at 4°C to obtain NPs with sizes less than
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~200 nm. After washing, CafA surface-modified NPs were suspended in 5 mL of
diH2O, frozen at -80°C, and lyophilized.
Surface-modified NPs encapsulating the fluorescent dye Coumarin 6 (C6)
or F-BAR were synthesized for binding, loading and controlled release studies. C6containing NPs were synthesized using an oil-in-water (o/w) single-emulsion
technique122,192. Briefly, C6 was dissolved in 200 μL dichloromethane (DCM)
overnight at a concentration of 15 μg/mg PLGA. In parallel, 100 mg of PLGA
crystals was dissolved in 2 mL of DCM overnight. The following day, the
PLGA/DCM solution was vortexed while adding C6 DCM solution and was
subsequently sonicated. Next, 2 mL of the PLGA/DCM/BAR solution was added
dropwise to mixture of 2 mL of 5% (w/v) polyvinyl alcohol (PVA) and either 2 mL
of 5 mg/mL avidin-palmitate or 2 mL of 4 mg/mL CafA-palmitate while vortexing
and was subsequently sonicated. Residual DCM was evaporated by adding the
NPs solution to 50 mL of 0.3% PVA for 3 hr while mixing. The same procedures
as described above were conducted to synthesize blank surface-modified NPs.
F-BAR-encapsulated CafA-modified NPs were synthesized similarly using
a double-emulsion technique. F-BAR was dissolved in 200 μL Tris EDTA buffer at
a concentration of 43 µg BAR/mg PLGA and protected from light during
synthesis143. All other conditions were as stated above.
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NP Characterization: NP Morphology, Size, CafA Conjugation, Controlled
Release
Unhydrated NP morphology, diameter, and size distribution were
determined using scanning electron microscopy (SEM, XL-30 ESEM-FEG SEM,
FEI Company, USA). Lyophilized NPs were mounted on carbon tape and sputter
coated with a thin layer of gold/palladium. Average diameters of 500 particles were
determined from SEM images (n=3) using image analysis software (ImageJ,
National Institutes of Health, version 1.5a, ImageJ.nih.gov). Dynamic light
scattering and zeta potential analyses were performed to determine the
hydrodynamic diameter and surface charge of hydrated NPs. The unhydrated and
hydrated diameters of NPs are typically assessed to establish the size
characteristics within different conditions of dry storage and more physiologically
relevant aqueous environments. Briefly, a 1 mg/mL sample of CafA-modified
PLGA NPs in diH2O was prepared. After vortexing and sonication, samples were
diluted at a 1:50 ratio in diH2O. One mL was aliquoted to the cuvette for analysis
(Malvern, Malvern, UK (Zetasizer Nano ZS90), courtesy of Dr. Martin O’Toole,
Univ. of Louisville) to measure dynamic light scattering and zeta potential with
Zetasizer Nano software. Samples were run in triplicate, using a refractive index
of 1.57 for PLGA, absorption coefficient of 1, and water refractive index of 1.33.
To measure the amount of CafA that was conjugated to the NP surface the
microBCA assay was conducted and compared to a CafA standard95,146. After
conjugation, NPs were centrifuged and washed twice with diH2O to remove
121

unbound CafA from the formulated NPs. NPs were then suspended in PBS:DMSO
(1:99) to create a 1 mg/mL NP solution and the resulting samples were transferred
to a microtiter plate in triplicate. Total NP-associated absorbance was determined
using Victor3 Multilabel spectrophotometer (562 nm), and the concentration of
CafA was determined from a standard curve of known CafA95.
For CafA-modified F-BAR-encapsulated NPs and unmodified F-BARencapsulated NPs, in vitro release was measured by gentle agitation of NPs in
PBS (pH 7.4) at 37ºC. At fixed time points (1, 2, 4, 8, 24 hr), samples were collected
and the amount of F-BAR released from the NPs was quantified by measuring
fluorescence (488/518 nm excitation/emission).
Stability of the CafA-NP Interaction
The stability of the CafA palmitate interaction with the NP surface was
tested by assessing the release of the CafA ligand from the NP surface with
respect to time. Similar to loading experiments, the CafA concentration was
determined using microBCA assay by measuring absorbance at 562 nm95,96 and
comparing to a standard curve of CafA.
Growth of Bacterial Strains
Pg (ATCC 33277) was grown in Trypticase soy broth (Difco Laboratories
Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL
menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently
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inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aerobically without shaking in brain-heart infusion broth (Difco Laboratories Inc.)
supplemented with 1% yeast extract for 16 hr at 37°C111-113.
Time-Dependent Binding of CafA-Modified NPs to Sg
The binding of CafA-modified NPs was compared to NPs that were modified
with the same density of a non-specific positively-charged protein, avidin, through
similar palmitic acid chemistry. Sg was harvested from culture and the bacterial
concentration was determined by measuring the O.D. at 600 nm from twenty-fold
diluted cultures of Sg. Sg cells were plated and then incubated with CafA-modified
and avidin-modified NPs. One hundred microliters of 0.2 OD Sg were added to the
96-well culture plate and incubated at 4°C overnight. The next day, wells were
blocked for non-specific binding with 300 µL of 0.3% bovine serum albumin (BSA)
for 1 hr. After washing three times with 1x phosphate buffer saline with 0.05%
Tween (PBST), 100 µL of CafA-modified C6 NPs (0.25 mg/mL), avidin-modified
C6 NPs (0.25 mg/mL) and PBST were added to wells in triplicate, and then
incubated on a rocker platform for 1 hr. After washing, the quantity of CafAmodified and avidin-modified C6 NPs binding to Sg was determined by measuring
the fluorescence (485/520 nm excitation/emission) after subtraction of the control,
in which Sg was incubated with PBST only, and this reading was considered as
time zero with 100% binding. One hundred µL of PBST were added to each well
and incubated with gentle agitation. After 1, 2, 4, 8, 12 and 24 hr the quantity of

123

CafA-modified and avidin-modified C6 NPs bound to Sg was determined by
measuring fluorescence.
Results
Quantification of the Total CafA Payload of CafA-Modified NPs
The amount of CafA bound to the NP surface directly correlated with the
input concentration of CafA, and the maximum surface density of CafA was
achieved by increasing the input concentration of CafA as shown in Figure 5.1. A
maximum density of 36 µg CafA/mg NP was incorporated on the PLGA NP surface
using an input concentration of 80 µg CafA per mg NP, yielding 45% conjugation
efficiency.
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Figure 5.1 The total amount of CafA bound to the surface of PLGA NPs was
determined using the microBCA assay. The amount of incorporated CafA on NP
surface is directly correlated to the input amount of CafA during fabrication.
CafA-modified Adhesion and Retention to Sg
To determine how long CafA-modified NPs remain bound to Sg,
streptococcal cells were immobilized and CafA-modified NPs or avidin-modified
NPs were incubated with Sg for 1 hr. The quantity of CafA-modified and avidinmodified C6 NPs initially bound to Sg after this hour was considered “time zero”
and was set to the maximum (100%) binding achievable. The quantity of CafAmodified NPs and avidin-modified NPs retained (remaining bound) after 1, 2, 4,
and 8 hr were determined, and compared to the amount bound during the initial 1
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hr period. As shown in Figure 5.2, after 1 hr, 5.7 µg of CafA-modified NPs were
bound to Sg, relative to 2.5 µg of the control, avidin-modified NP group, resulting
in a 2.3-fold increase in binding, due to CafA surface modification. After 8 hr, 3.7
µg of CafA-modified NPs and 1.4 µg of avidin-modified NPs were bound to Sg,
resulting in a 2.5-fold increase in binding (Figure 5.2A). This corresponded to 65%
of CafA-modified NPs and 56% of non-specific avidin-modified NPs bound,
suggesting that surface modification with CafA strongly impacts NP adhesion and
retention (Figure 5.3B).

In addition, CafA-modified NPs demonstrated stronger

initial binding and a similar but less pronounced decrease in binding with respect
to time, relative to avidin-modified NPs.

Figure 5.4 (A) CafA-modified C6 NPs initially (t = 0) bind to Sg with 2.3-fold greater
concentration (5.7 ug/mL), relative to avidin-modified C6 NPs (2.5 µg/mL) and
maintain a 2.5-fold increase in binding (3.7 µg/mL) after 8 hr, relative to avidinmodified C6 NPs (1.4 µg). (B) 65% of CafA-modified C6 NPs retain binding to Sg
after 8 hr.
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Quantification of BAR Release
To assess BAR release from the NPs, the fluorescence of supernatant from
1, 2, 4, 8, 24 hr release time points was measured and compared to a known
standard of F-BAR in PBS. Loading experiments demonstrated that both
unmodified and CafA-modified PLGA NPs highly encapsulated BAR with 16.95 ±
0.8 and 15.73 ± 1.9 µg of BAR per mg of NP, respectively, corresponding to
encapsulation efficiencies of 39.4 and 36.5% (Table 5.1). Release experiments
demonstrated that 10.3 µg/ml of encapsulated BAR was released from CafAmodified BAR-encapsulated NPs, while 15.5 µg/mg of encapsulated BAR was
released from unmodified BAR-encapsulated NPs within 24 hr (Figure 5.3).
Table 5.1 The amount of BAR (µg) loaded in unmodified and CafA-modified NPs
(mg).
NP Type

BAR input
(µg/mg)

BAR output
(µg/mg)

Encapsulation
Efficiency (%)

Unmodified NPs

43

16.95 ± 0.8

39.4

CafA-modified NPs

43

15.73 ± 1.9

36.5
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Figure 5.5 (A) Cumulative release of BAR as a function of mass (µg BAR per mg
NP) and (B) percent of total BAR loaded over 24 hr.
Stability of the CafA-NP Interaction
The stability of CafA binding to the NP surface was assessed by incubating
CafA-modified NPs with agitation in 1x PBS at 37°C for 24 hr. Quantification of
CafA release into the supernatant after 1, 2, 4, 8, and 24 hr was evaluated using
the microBCA assay, and the percent of CafA retained on the NP surface relative
to the amount loaded was determined. Over 82 ± 3% of the initial CafA remained
conjugated to PLGA NPs after 24 hr indicating a stable interaction with the NP
surface (Figure 5.4).
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Figure 5.6 Percent of CafA retained on the PLGA NP surface after 24 hr.
Thus far we have established this approach to fabricate CafA-modified
BAR-encapsulated NPs with a high and stable surface density of CafA. CafAmodified NPs highly encapsulated BAR peptide with more gradual and increased
release, relative to unmodified BAR NPs. These results suggest that CafAmodified NPs may be a promising platform to maintain BAR concentration in the
oral cavity for 12 to 24 hr for once or twice daily application. In addition, studies
demonstrate the utility of modifying BAR-encapsulated NPs with CafA to achieve
efficient binding and retention to Sg for at least 8 hr, relative to avidin-modified
NPs.
The next steps we envision are to assess the functional activity of CafA-modified
BAR-encapsulated NPs against novel 3D dental mimetic tissue with dual-species
biofilm in vitro and in murine model of periodontitis.
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CHAPTER 6
OVERALL DISCUSSION AND CONCLUSION
Periodontal disease is a group of chronic inﬂammatory diseases that is
globally prevalent, affecting ~46% of U.S adults and 30-50% of people globally.
Porphyromonas gingivalis has been identified as a “keystone” pathogen involved
in the initiation and progression of periodontal inflammatory disease, by disrupting
host-microbe homeostasis and inducing population changes in the subgingival
biofilm108. This disruption and colonization is initially prompted by association of
Pg with oral streptococci in the supragingival niche, and is thus an ideal target for
therapeutic intervention9.
Previous work in our groups has shown that a region of the streptococcal
antigen denoted BAR inhibits Pg/Sg interaction and biofilm formation both in vitro
and in a murine model of periodontitis111-113. Moreover, recent studies
demonstrated the potential of BAR surface-modified PLGA nanoparticles to deliver
a high localized concentration of peptide to subgingival niches 95. While surfacemodified NPs were shown to potently inhibit biofilm formation via multivalency, the
development of a formulation that can release BAR peptide, within a time frame
relevant to oral delivery, had not been investigated.
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Moreover, the potential of a new dosage form that might increase the
convenience and flexibility of administrating a specific peptide into the oral cavity
had not been explored by our groups. With this in mind, the aims of this dissertation
were to translate our previous in vitro BAR-modified NP work to a murine model of
periodontitis95, investigate the potential of novel BAR-encapsulated NPs to inhibit
and disrupt biofilm formation for prolonged durations relevant to oral delivery, and
develop rapid-release BAR-EFs that may, in future work, be applied twice daily to
release therapeutically relevant concentrations of BAR in the oral cavity.
To date, a variety of groups have developed polymeric delivery vehicles to
improve traditional prevention and treatment approaches to periodontal
diseases86. However, polymeric delivery vehicles have been primarily developed
to deliver antibiotics85,86,90,152,153 for prolonged durations, and to decrease antibiotic
dose, administration frequency, and associated adverse effects. However,
antibacterial resistance and non-specificity still remain challenges to effectively
eradicate initial and recurrent biofilms, pathogen resistance, and associated
diseases35,37,107.
While recent studies have demonstrated some success using various
polymeric NPs in dental pathogen murine models85,86, these studies have focused
on targeting antibiotic NP formulations to epithelial cells with gingival targeting
RGD peptides. Results from these studies indicated that NP surface-modification
improved NP attachment to epithelial cells, maintaining antibacterial (i.e.,
minocycline) concentrations in gingival fluid for prolonged durations and improved
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therapeutic activity relative to unmodified NPs94. Other studies have similarly
sought to use RGD94, or more general bioadhesive molecules such as
chitosan124,126 or dimethyl-octyl ammonium134, to obtain improved localization and
adhesion to the dental surface. Strong mucoadhesive properties and adhesion to
the tooth surface124 were demonstrated for antibacterial NPs modified with these
agents.
Polymeric electrospun fibers have been used as delivery vehicles in several
biomedical

applications

including

wound

dressing

materials158,

tissue

regeneration159,160, and as drug delivery vehicles for bioactive molecules,
antimicrobial agents193, anti-inflammatory drugs170, and anesthetics171. Moreover
fibers have provided cell scaffolds with PLGA EFs160, in combination with PCL
and PLA to deliver doxycycline193 and metronidazole98.
Specific to oral delivery, electrospun fibers have been investigated for
antibiotic,

anti-inflammatory

regeneration, and

and

analgesic

delivery,

periodontal

tissue

to act as implantable drugs and growth factor-releasing

scaffolds that help repair surgical sites97,160,170,171. Previous studies demonstrated
that metronidazole-loaded PLA or PCL fibers showed sustained-release of
metronidazole with potent antibacterial activity, however poor wettability and
stiffness limited the use of PLA and PCL alone without hydrophilic fiber blend for
local periodontitis treatment98,172. In addition, PLA:PCL/Gelatin fibers containing
tetracycline demonstrated significant inhibition of oral biofilms in vitro, suggesting
that tetracycline-loaded fibers may act as potent antibacterial implant for dental
132

application; however, non-specific activity of tetracycline may affect the growth of
commensal beneficial oral bacteria174.
In comparison with limited and mostly non-specific approaches to prevent
or treat periodontal diseases, the goal of this work was to incorporate a pathogenspecific biological active agent within a NP surface modification or encapsulation,
to exploit the specific and adhesive interactions between two bacteria known to
initiate the process of periodontal infections. We showed that not only can this
specific peptide target biofilm interactions, but that by conjugating BAR to a NP
surface or encapsulating BAR within PLGA NPs or EFs, we can achieve safe and
enhanced potency, attributed to multivalency and prolonged activity, in a murine
model of infection and in vitro. Moreover, the use of biodegradable FDA-approved
polymers as a core platform, offers the potential for the incorporation of other
complementary active agents, and more seamless integration in pre-clinical and
clinical studies.
Lastly, while BAR-encapsulated and BAR-modified NPs demonstrate
significant promise, their retention in the oral cavity is considered to be a challenge
regardless of active agent and delivery vehicle. To address this challenge, our
ongoing studies are focused on first developing NP formulations that can localize
and retain BAR for longer durations in the oral cavity by using CafA-modified NPs
to target Sg in oral niches.
Certainly, the drug delivery system plays a vital role in controlling the
therapeutic effect of the active agent through optimizing the rate of drug release.
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Many dosage forms are designed to release the active agent immediately (rapidrelease) or provide delayed (prolonged) and extended-release products.
Extended-release dosage forms can consist of sustained-release formulations that
release agents over a specific time period, or controlled-release formulations that
maintain the release of active agent at a constant rate for a specific duration194.
In the long-term, we seek to formulate BAR-modified NPs or CafA-modified
BAR-encapsulated NPs to more conveniently administer to the oral cavity in a
mouthwash, oral varnish or gel formulation, with the goal of retaining BAR in oral
niches for durations spanning 12-24 hr. In addition, our results utilizing BARincorporated EFs to inhibit oral biofilm formation raise the possibility that this
formulation can be developed in the form of strips or gum to release peptide over
a time window of hours. We envision that formulating this extended-release
platform may be applied once or twice daily to exert prophylactic effect in the oral
cavity without the need to remove the fibers after application.
Conclusion and Future Work
Incorporation of BAR peptide in NPs provides gradual release of BAR
peptide, while offering a platform to improve efficacy and potentially longevity in
the oral cavity, compared to the transient activity of free BAR. In addition, BARincorporated EFs may provide an alternative and specifically-targeted rapidrelease platform to inhibit and disrupt dual-species biofilms, that we envision may
be applied once or twice daily to exert prophylactic effect in the oral cavity without
the need to remove the fibers after application. BAR-modified NPs offered a
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platform that provided higher localized concentration of BAR in the oral cavity via
multivalent interactions.
In future studies, we intend to examine different temporal administration
regimens to optimize prevention and treatment approaches with these platforms.
In addition, we plan to extend our studies to assess the kinetics of BAR-delivery
vehicles in the oral cavity after gingival application.
In the longer term, we seek to formulate these NPs into a mouthwash or gel
for more convenient application to the oral cavity. In addition, we envision BAREFs may be administered as dental strips or in gel form to degrade and avoid
surgical removal after application. While existing products designed for localized
periodontal prevention and treatment contain antibiotics, analgesic, or anesthetic
cargos, we envision that this technology may offer a new way to deliver
specifically-acting biologics to the oral cavity.
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